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Abstract: 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The median age 
of diagnosis is 64 years, with an increasing number of patients diagnosed over the age of 
seventy. Managing elderly patients with this condition is challenging. Management pathways 
may include surgery, radiotherapy (RT), chemotherapy and best supportive care (BSC). Many 
clinical trials in oncology exclude elderly patients, including some of those for malignant brain 
tumors leaving less evidence to guide treatment in the these patients. Recent advances in 
molecular diagnostics and biomarkers, such as 06-methylguanine-DNA-methyltransferase 
(MGMT) promoter methylation status, may help guide optimal treatment selection. Focusing on 
available randomized data, this review provides a practical overview of the evidence for the 
treatment of newly diagnosed glioblastoma in the elderly including management 
recommendations.  
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Convention is to define the ‘elderly’ population as exceeding a specified chronological 
age which varies with temporal, geographical, social and cultural factors. Managing elderly 
patients can be challenging; medical comorbidities, multiple concomitant medications, and 
increasing fragility of health alter drug efficacy and the magnitude and spectrum of adverse 
effects related to treatment. With age, the natural insidious change of physiology and constitution 
affects pharmacokinetic processes with regards to absorption, metabolism, distribution and drug 
clearance.
1
 Many clinical trials in oncology exclude elderly patients, including some of those for 
malignant brain tumors; as such there is less evidence to guide treatment in the elderly cohort.  
This review provides a practical overview of the evidence for the treatment of newly diagnosed 
glioblastoma in the elderly.  
 
 
Epidemiology 
 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The 
Central Brain Tumour Registry of the United States (CBTRUS) statistical report, which collates 
epidemiological data from over 50 state cancer registries, identified 112,458 malignant primary 
brain and central nervous system (CNS) tumors between 2006 and 2010 of which 45.2% were 
glioblastomas.
2
 A median age of 64 at diagnosis and an average age-adjusted incidence rate per 
of 3·19 (3·16-3·21) per 100,000 were reported. Stratification by age detected an increase in 
incidence with age, and the peak rate of 14·93 in the 75-84 age range. Of note is the marked 
decrease in survival with advancing age (table 1). The 1-year and 2-year relative survival rates of 
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40·7% and 14·2% for patients aged 55-64 falls to 9·2% and 2·6% for patients aged 75 or older.  
An Ontario (Canada) population-based cohort study of all patients diagnosed with glioblastoma 
between 1982 and 1994 found poorer survival with respect to each increasing decade of age 
(Figure 1 courtesy of Paszat et. al. Unpublished 1999). Whether this poorer survival is a 
reflection of differing provisions of care based on chronological age or reflects more aggressive 
tumor biology, or both, is presently unclear.   
 
The histologic hallmarks of glioblastoma, as defined by the World Health Organization 
(WHO), include cellular polymorphism, nuclear atypia, a high mitotic index, microvascular 
proliferation and necrosis.
3
 With the emergence of personalized medicine, molecular diagnostics 
are increasingly used to improve the treatment and survival associated with glioblastoma.  
Prognostic biomarkers such as TP53 mutation, 1p deletion, cyclin dependent kinase (CDK) 
N2A/p16 deletion and epidermal growth factor receptor (EGFR) amplification vary with age
4
. In 
a histological review of 140 patients, TP53 mutations and EGFR amplification had differing 
prognostic significance when stratifying by age, with TP53 mutations being positively prognostic 
for younger patients and negative for older patients (<70yrs 0.84; 95% CI 0.49 –1.42 versus 
>70yrs HR 7.54; 95% CI 2.38–23.87)4. Conversely EGFR amplification in the context of older 
patients was positively prognostic yet in younger patients it was negatively prognostic.
4
  
 
More recently gene expression-based molecular analysis has been utilized to categorize 
glioblastoma into subtypes including proneural, neural, classical and mesenchymal subtypes.
5
 
Lee et al. performed a meta-analysis which substantiated the presence of these subtypes, as 
identified by genetic signature and suggested that the prognostic effect of age may in fact be a 
reflection of the differing prevalence of specific subtypes at differing ages; for example the 
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proneural subtype appears to occur more often in younger patients and is associated with longer 
survival.
6
 Presently these markers do not have a defined role in clinical practice with regards to 
daily management decisions and remain under investigation.  Of note, positive prognostic 
biomarkers, like mutations of isocitrate dehydrogenase (IDH) are virtually absent in 
glioblastoma of the elderly; similarly the general DNA methylation levels in the tumor tissue 
seem to be low. Despite this the frequency of O6-Methylguanine-DNA methyltransferase 
(MGMT) promoter methylation, itself an important positive predictive marker, does not vary 
with age.
7
 
 
Surgery  
In younger patients, maximal safe resection is advocated with the intent of preserving 
neurological function, providing maximal tissue for molecular profiling, and improving overall 
survival. Analysis of the extent of surgery in Radiation Therapy Oncology Group (RTOG) 
randomised trials, found significant improvement in survival with partial/total resection versus 
biopsy alone.
8
 Review of an unselected population of 345 newly diagnosed glioblastoma patients 
from the German Glioma Network (GGN) demonstrated gross tumour resection to be associated 
with superior overall survival (OS) (median 17·1 months) compared to incomplete resection 
(median 11·7 months) and biopsy alone (median 8·7 months).
9
 A multivariate analysis of 416 
glioblastoma patients treated at a single institution between 1993 and 1999 reported resections of 
tumour volume in the order of 98% or greater to be associated with significant survival 
advantage (median survival 13 months, 95% CI 11·4–14·6 months versus 8·8 months (95% CI 
7·4–10·2 months; p < 0·0001).10  
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There is one randomized trial pertaining to surgical intervention, including elderly 
patients with glioblastoma. This small study of 30 patients assessed the role of debulking surgery 
compared to biopsy alone.
11
  Patients aged 65 or older with KPS >60 were randomized to open 
craniotomy and resection [14 patients with a median age of 70 (66-80)] or stereotactic biopsy [16 
patients with a median of age 72 (67 -79)]. Surgical resection resulted in superior overall survival 
(171 days (95% CI 146–278) vs. 85 days (95% CI 55–157) p = 0·0346). More recently, a case-
control study with a subgroup analysis of 52 patients aged 70 or over found a median survival of 
4·5 months and 3 months for surgical resection and needle biopsy respectively (p = 0·03).
12
 
Perhaps the most relevant trial for the topic is the Neuro-oncology Working Group of the 
German Cancer Society NOA-08 study which found extent of surgery to be an independent 
prognostic factor for overall survival among glioblastoma patients 65 years and older.
13
 
Furthermore, multivariate analysis of all patients (n=342) participating in the Nordic trial of 
standard vs. hypofractionated radiotherapy vs. chemotherapy alone in newly diagnosed 
glioblastoma patients 65 years of age or older also demonstrated a survival benefit favoring 
surgery over biopsy alone (biopsy versus resection HR 1·50 (1·17 -1·92) p =0·001).
14
 
 
Standard post-operative management for newly diagnosed glioblastoma 
The European Organisation for Research and Treatment of Cancer (EORTC) 26981-
22981/National Cancer Institute of Canada Clinical Trials Group (NCIC) CE.3 randomised phase 
III trial assessed the addition of temozolomide (TMZ) to radiotherapy (RT) in the concomitant 
and sequential adjuvant setting in glioblastoma patients aged 18-70.
15
  Median age was 56 (range 
19-71) and the selected population required Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–2. The addition of TMZ resulted in a median survival benefit of 2·5 
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months; 14·6 months (95% CI 13·2- 16·8) compared with 12·1 months (95%CI 11·2 -13·0) for 
radiotherapy alone. The 5-year analysis of this trial confirmed a persisting advantage and this has 
become the standard of care post-surgical resection for patients less than 70 years of age and of 
appropriate performance status.
16
 In a recent review Laperriere et. al. noted that subgroup 
analysis of this trial demonstrated a trend to benefit in the more elderly subgroups, albeit with a 
less impressive hazard ratio and without reaching statistical significance. Specifically, there was 
diminishing benefit of combined treatment with increasing age (61-65 years: HR 0.64 p = 0.096 
and 66–70 years: HR = 0·78 p = 0·34) compared to the overall group (HR 0·6, 95%CI 0·5-0·7; 
p<0·0001).
17
 This may reflect less robust effects of the combined approach in the elderly or may 
be due to lower statistical power in the subgroup analysis. 
 
Radiation for elderly patients 
Randomized trials have long demonstrated a survival benefit from post-operative 
radiotherapy in the management of glioblastoma and more recently several trials have focused on 
the elderly. The French ANOCEF group found a median survival benefit of 12.2 weeks in favour 
of RT plus best supportive care (BSC) versus BSC alone.
18
 Patients aged 70 or older with a KPS 
>70 and a diagnosis of glioblastoma or anaplastic astrocytoma were randomized postoperatively 
to receive BSC [(42 patients (median age 73; range 70-85)] or BSC and 50 Gy in 1.8 Gy 
fractions to a clinical target volume (CTV) consisting of enhancing tumour with a 2cm margin 
[(39 patients (median age 75; range 70-84)]. Overall survival was 16·9 (95% CI, 13·4 to 21·4) 
and 29·1 weeks (95% CI, 25·4 to 34·9) respectively. No significant difference was detected with 
regards to quality of life; however, Health Related Quality of Life (HRQoL) assessments were 
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incomplete.  Cox proportional hazard modelling revealed that extent of surgery was associated 
with increased survival.  
Scott et al. performed a large retrospective review of elderly glioblastoma patients 
diagnosed between 1993 and 2005.
19
 The study sample of 2836 patients identified from the 
Surveillance, Epidemiology, and End Results (SEER) registry database had a median age of 76·9 
years (range 71·0–98·0). Kaplan-Meier analysis revealed median cancer-specific survivals of 8 
months for patients undergoing both surgery and postoperative radiotherapy, 4 months for 
radiation alone, 3 months for surgery alone and 2 months for neither surgery nor radiotherapy 
(log rank p<0·001). Multivariate analysis suggested radiotherapy significantly increased cancer-
specific survival after adjusting for tumour size, tumour location, surgery and patient 
demographics with a hazard ratio (HR) of 0·43 (95% CI, 0·38–0·49). 19 
The biological effect of radiation on tumour and normal tissues is dependent upon the 
provision of dose over time as well as intrinsic radio-sensitivity (α) and repair capability (ß). 
Glioblastoma has an alpha-beta ratio (α/ ß) = 8Gy (5·0–10·8)20 which is in the range of most 
tumours, while the alpha-beta ratio is approximately 2 for the normal central nervous system. As 
a result of this difference, hypofractionation reduces overall treatment time and may minimize 
the potential for tumor cell repopulation and provides a practical convenience for an elderly frail 
population. Roa et. al. randomized patients aged 60 or older to radiotherapy given as 60Gy in 30 
fractions (47 patients, mean age 72.4 yrs, SD 5·4) or a hypofractionated regimen of 40Gy in 15 
fractions (48 patients, mean 71·0 yrs, SD 5·5).
21
 While this study was not sufficiently powered to 
conclude equivalence of these two fractionation schedules it suggested no significant differences 
in OS [median 5.1 months for the standard RT arm versus 5·6 months for the shorter course (log 
rank p = 0·57)], survival at 6 months (44·7% standard RT versus 41·7% hypofractionated RT), or 
10 
 
HRQoL.  More patients required an increase of corticosteroid dose following the standard 
radiotherapy schedule compared to the hypofractionated course (p= 0·02). 
The Nordic trial incorporated a different hypofractionated radiotherapy schedule.
14
 There 
were 3 treatment arms including standard radiotherapy of 60Gy in 30 fractions, hypofractionated 
radiotherapy of 34Gy in 10 fractions or temozolomide 200mg/m2 days 1-5 every 28 days for up 
to 6 cycles. Standard radiotherapy (60Gy/30) was not routinely offered to elderly patients in 
some study sites so randomization between just the hypofractionated radiotherapy and 
temozolomide arms was permitted.  Two hundred and ninety one glioblastoma patients (initially 
aged 60 years or older then in view of EORTC 26981-22981/NCIC-CTG CE.3 the age eligibility 
was adjusted so that patients 60-65 years old fit for combined treatment were excluded) were 
randomized to standard radiotherapy (n=100), hypofractionated radiotherapy (n=98) or 
temozolomide alone (n=93). A further 51 patients were randomized to either hypofractionated 
radiotherapy (n=25) or TMZ (n=26) by those centers that did not offer 60Gy in 30 fractions as 
their standard care. 
The median age was 70 for both the hypofractionated and the standard radiotherapy 
groups. Median survival in the hypofractionated group was increased by 1·5 months compared to 
standard radiation in the three-arm comparison. Interestingly, on stratification by age, the 
advantage of hypofractionated radiation appeared better in patients over the age of 70 (7·0 (5·2–
8·8) versus 5·2 (4·0–6·3) months). Treatment completion according to protocol was more 
frequent with the hypofractionated schedule (95% versus 72%). Salvage treatment was received 
for a similar proportion of patients in both groups while reported toxicity was not different 
between groups.   
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Temozolomide and O-6-methylguanine-DNA methyltransferase  
The alkylating agent TMZ has activity in glioblastoma, and in combination with 
radiotherapy followed sequentially by a 6 month maintenance course represents the current 
standard of care for many patients. The mechanism of anti-tumour activity is believed to arise 
through methylation of DNA at the O-6 position of guanine by monomethyl-triazeno-imidazole-
carboxyamide (MTIC), a non-enzymatic chemical degradation product of temozolomide.
22
     
MGMT is a DNA repair protein implicated in resistance to alkylating agents.
23
  
Methylation of the MGMT promoter, located at 10q26, leads to suppression of MGMT gene 
expression and an increased likelihood of clinical benefit.
23-25
 Hegi et al. assessed the MGMT 
promoter methylation status of patients randomized in the EORTC trial 26981/ NCIC CE.3 
trial.
25
 Regardless of treatment arm, OS was longer in patients with MGMT promoter 
methylation; 18.2 months compared with 12.2 months [HR for death 0·45 (95% CI 0·32 - 0·61)]. 
The magnitude of this effect was more substantial for patients receiving TMZ compared with 
those receiving radiation alone (P=0·007 vs. P=0·06, log-rank test). Of note, the majority of 
patients allocated to radiotherapy alone received alkylating agent chemotherapy as salvage 
treatment further supporting the use of concomitant therapy ‘upfront’ in newly diagnosed 
patients.
25
 The prognostic significance of MGMT promoter methylation status was prospectively 
corroborated in the RTOG 0525 randomized study of TMZ dose density in the adjuvant setting. 
In this study, dose-dense TMZ (n=422) failed to demonstrate a survival advantage over standard 
dosing (n=411).
26
 The absence of a TMZ-free control arm did not allow distinction between 
prognostic and predictive properties. 
12 
 
For elderly patients not suitable for the combined modality approach, recent evidence 
supports consideration of TMZ alone particularly for tumors harbouring MGMT promoter 
methylation.
27
 Temozolomide alone was assessed in the Nordic study,
14
 which found longer 
survival for both TMZ alone and hypofractionated radiotherapy over standard radiotherapy in 
patients older than 65 years of age. Comparison of TMZ and hypofractionated radiotherapy 
revealed no significant difference in overall survival (7·4 versus 8·4 months HR 0·82 95%CI 
0·63-1·06). In the head to head comparison of TMZ versus hypofractionated radiation, 36% of 
the TMZ recipients had subsequent radiation and 29% of the hypofractionated group had salvage 
chemotherapy. MGMT promoter methylation status was available in 258 (75%) of 342 patients. 
Patients with MGMT promoter methylated tumors receiving TMZ survived 2.9 months longer 
than those with unmethylated tumors (HR 0·56, 95% CI 0·34-0·93, p=0·02). No survival 
advantage was identified based on MGMT promoter methylation status within the cohort 
receiving radiation (HR 0·97, 95% CI 0·69-1·38, p=0·81). Although the intent for the TMZ group 
was to complete six cycles, at least two cycles were administered to 86% of patients, and only 
34% completed all six cycles. Haematological toxicity as well as nausea and vomiting were more 
frequent as would be expected in the TMZ cohort. In addition, a treatment-related death 
involving thrombocytopenia highlights that prescribing chemotherapy is not without the potential 
for serious toxicity. 
 
In the NOA-08 study,
13
 192 patients received TMZ (1 week on, 1 week off schedule 100 
mg/m2 days 1–7) and 178 patients received 60Gy radiotherapy alone over 6–7 weeks to the 
gross tumour volume (GTV) + 2 centimeters. Median overall survival was similar for the two 
treatment arms: 8·6 months in the TMZ group and 9·6 months in the radiotherapy group (HR 
13 
 
1·09, 95% CI 0·84–1·42, p non-inferiority=0·033). MGMT promoter methylation status was 
available in 55% of patients receiving TMZ and 57% of patients receiving radiation with a 
predictive benefit seen for patients receiving the alkylating agent in the context of MGMT 
promoter methylated tumors. Hematological toxicity, abnormal liver function tests, infections 
and thromboembolic events were more prevalent in the TMZ group.  
 
These trials found that MGMT promoter methylation is a predictive biomarker of benefit 
from TMZ, but not radiotherapy. The randomized international NCIC/EORTC/TROG study, 
which completed accrual in September 2013 (JP, personal communication), aims to address the 
potential benefit of combining short course radiotherapy (40Gy in 15 fractions) with concurrent 
and adjuvant TMZ in patients over 65 years who have had prior surgery/biopsy at diagnosis and 
are not deemed suitable for the standard radiotherapy regimen of 60Gy.
28
 MGMT status will be 
assessed in this study. 
A phase 2 ANOCEF study suggests that older age and poor KPS should not preclude the 
use of TMZ alone.
29
 This was a non-randomized study which recruited 70 patients with a median 
age of 77 (range 70-87) and a median KPS of 60 (range 30-60). Intriguingly this study found an 
improvement of KPS in excess of 10 for 23 (33%) of treated patients with 18 (26%) having a rise 
to 70 or more. A maximum of 12 cycles of TMZ was planned however the median number of 
cycles received was only 2 with 20% and 24% of patients having dose delays and dose 
reductions for hematological toxicity respectively. Grade 3 or 4 hematological toxicities were not 
insignificant with 13% experiencing grade 3-4 neutropenia and 14% grade 3-4 
thrombocytopenia. No deaths were attributed to treatment. Although only 44% of patients were 
able to have tumor material assessed for MGMT promoter methylation, this study again 
14 
 
demonstrated its predictive role with a hazard ratio for death of 2.307(95% CI 1.073 to 4.962) for 
patients with unmethylated MGMT promoter status (P=0·03). This phase II study introduces the 
question – should more elderly patients with poor performance status be primarily treated with 
TMZ monotherapy? Or should TMZ monotherapy be employed only in those whose tumor 
harbors a methylated MGMT promoter?    
Although MGMT promoter methylation status is increasingly available it still not used in 
all centres. In the future increasing evidence favoring MGMT testing is likely to demand more 
widespread availability; for example the European Association for Neuro-Oncology (EANO) 
guideline for the diagnosis and treatment of malignant gliomas has already declared that MGMT 
promoter methylation status testing is standard of care
30
.  There have been some controversies 
regarding the methodology of MGMT testing, with some centers preferring pyrosequencing and 
others utilizing PCR. Immunohistochemistical assessment of MGMT does not appear to correlate 
with overall survival.
31
 
 
Bevacizumab 
Three uncontrolled studies indicate that the vascular endothelial growth factor (VEGF) 
antibody bevacizumab may have increased activity in elderly patients with glioblastoma.
32-34
 In 
2014, the efficacy of bevacizumab in newly diagnosed glioblastoma patients has been reported 
by two large, placebo-controlled, randomized trials.
35,36
 The Avastin in Glioblastoma (AVAglio) 
phase III study evaluated the effect of the addition of bevacizumab to focal radiotherapy with 
concurrent TMZ, to the adjuvant component and then beyond the adjuvant component until 
progression.
34
 Although improved progression-free survival (HR 0·65 (0·56–0·75)), preservation 
of baseline quality of life and performance status were reported, there was no improvement in 
15 
 
overall survival. Stratified by age over 70 years, the statistical significance with regards to PFS 
was lost [HR 0·78 (0·46–1·33)]; however this may reflect an issue of statistical power and small 
subgroups rather than a lack of clinical efficacy.  The RTOG 0825 trial, sharing a similar design, 
also failed to demonstrate an overall survival benefit
35
 but in contrast to the AVAglio study, a 
greater deterioration clinically assessed by patient reported outcome questionnaire, was evident 
in the bevacizumab group. There were differences in the design of these two studies that may 
influence determination of progression and patient reports outcomes.  Radiological assessment in 
the RTOG 0825 study was by serial measurement of cross-sectional diameter and use of the 
international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)
37
 
committee whereas the AVAglio study utilized an adaptation of the Macdonald criteria, similar 
to the newer RANO criteria, which takes into account the issues of pseudoprogression, 
pseudoresponse and changes in the non-enhancing disease.
38  
Ongoing discussion and analyses 
may further clarify the apparent discordant results with regard to progression-free survival  in 
these two pivotal trials.  
 No clinical or tissue based biomarkers have yet been prospectively shown to be 
associated with benefit from bevacizumab although patients with glioblastomas harbouring a 
proneural subtype may derive the most benefit.
39
 At present bevacizumab has no role in the 
standard upfront treatment of glioblastoma; however, future clinical trials may attempt to target 
specific groups of patients defined by sets of biomarkers. The randomized Avastin plus 
Radiotherapy in Elderly Patients with Glioblastoma (ARTE) study, a phase II trial, will explore 
whether the addition of bevacizumab to radiotherapy improves outcome in elderly patients with 
newly diagnosed glioblastoma without MGMT promoter methylation (M. Weller, personal 
communication). 
16 
 
Symptomatic management  
Glioblastoma can cause many difficult symptoms ranging from fatigue to those 
associated with raised intracranial pressure. Seizures may often occur as well as cognitive, motor 
or sensory deficits occurring in a location-dependent manner. Corticosteroids are often required 
to control symptoms of cerebral edema and their utility over time must be balanced with 
potential side effects such as proximal myopathy, steroid-induced diabetes, and osteoporotic 
fractures which can be debilitating. Furthermore, corticosteroids may reduce the benefit from 
TMZ in the most promising MGMT promoter methylated subgroup.
40 
Anti-seizure medications 
are also often warranted.  There is no randomised evidence pertaining to palliative care in the 
glioblastoma setting. However, based on a randomised study in non-small lung cancer, which 
demonstrated the addition of palliative care not only improved quality of life but also increased 
overall survival, many would advocate the early incorporation of palliative care support.
41
  
 
Population-based retrospective studies 
For glioblastoma, like many other cancers, results from randomized clinical trials (RCTs) 
may not reflect ‘real world” outcomes as described in population based studies. Several large 
population based studies have shown that many elderly patients do not receive the ‘gold 
standard’ treatment.  For example, despite the increasing body of evidence regarding the 
important benefit of resection rather than biopsy, numerous international pattern of care 
studies
42-46
 demonstrate a much higher rate of biopsy alone rather than attempted resection in the 
elderly population. 
The SEER database study published by Scott et. al. reported that among 2836 patients, 
only 46% of those over the age of 70 received both surgery and radiotherapy, with omission of 
17 
 
treatment associated with poorer survival.
19
 A similar SEER study of 4,137 patients with 
glioblastoma, aged 65 or older, reported a median overall survival of 4 months and described age 
to be associated with lower odds of resection and provision of RT or chemotherapy.
19
 The 
Princess Margaret Cancer Centre published outcomes of 131 patients aged greater than 70 
treated in the ‘temozolomide era’ between 2004 and 2008.47  Elderly patients were more likely to 
receive best supportive care or ‘palliative’ doses of radiotherapy with only 1 patient receiving 
60Gy in 30 fractions in combination with TMZ. Only 6 patients (5%) received TMZ post-
radiation, with only a median of 2.5 cycles administered.  A retrospective review of 235 patients 
aged 65 or over treated between 2006 and 2013 at the Odette Cancer Center in Toronto provides 
a more contemporary overview regarding provision of care in the elderly setting.
48
 With a 
median survival of approximately 2 months, 19% of patients were deemed not suitable for active 
treatment. 
There is a likely another subgroup of elderly patients not reflected in statistics who might 
be presumptively diagnosed on radiological investigations (e.g. imaging for suspected stroke) but 
for various reasons (e.g. comorbidities, patient and family preference) do not proceed even to a 
biopsy. Of course, in certain scenarios, e.g. bedbound patient with dementia, it may be 
inappropriate to pursue active management. 
Survivorship in the ‘real world’ would appear less favorable to that quoted in RCTs and 
may be a reflection of both physician preference to not to administer treatment in a group 
previously not studied as well as patient choice. A patient-centered approach is important, as in 
all aspects of medicine, and treatment decisions need to involve a patient’s own preferences and 
goals of care should be a focus early in the discussion regarding management.   
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Practical aspects: 
Practical considerations such as performance status and even the ability of the patient to 
get to appointments can also come into play, as many of these patients are no longer driving. For 
example, a mobile elderly patient with a poor short-term memory, but with a strong family 
network advocating for active treatment, is far more likely to be treated than a socially isolated 
patient. If a cognitively intact patient with poor mobility is keen for treatment; again the presence 
of supportive family will often make a difference impacting on decision-making. 
Often rehabilitation is not offered for glioblastoma patients postoperatively. However, 
there is evidence that postoperative rehabilitation in this setting is just as useful as in the stroke 
setting
49,50
 and should be considered where possible. There are observational studies which show 
improvement in patients’ functional status during the course of rehabilitation therapy, including 
the functional independence measure (FIM)
51,52
 and referral for rehabilitation is advocated.
53
 
Elderly patients and their caregivers may have numerous symptoms or challenges ahead. 
Challenges include treatment and tumor-related symptoms and deficits, seizures, headaches, 
communication difficulties (e.g. expressive or receptive aphasia), personality and behaviour 
changes (e.g. frontal syndrome with disinhibition and emotional lability), poor concentration, 
poor memory, fatigue, weakness, mobility; hemiparesis, impaired judgement/insight and 
depression (reactive versus major). These challenges can be even more difficult to manage in the 
setting of comorbidities and polypharmacy often faced by elderly patients. 
The clinical journey is a complex one and can involve interaction with many health 
professionals- including neurosurgeon, radiation oncologist (and radiation therapists), medical 
oncologist, palliative care physician, occupational therapist, physiotherapist, neurologist, 
endocrinologist (for steroid-induced diabetes) or diabetic educator, social worker, pharmacist, 
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psychologist, speech pathologist etc. and ideally a cancer care coordinator should be available, 
where possible, to help the patient navigate through this difficult pathway. 
Caregiver burnout is also very important for clinicians to be aware of. Recent studies 
have demonstrated that the global quality of life is often poorer in the caregiver than in the 
patients themselves.
54,55
 Often, in the elderly setting, a spouse (if there is one) has their own co-
morbidities to deal with and struggles to manage both physically and emotionally with the 
complexities involved with caring for a partner with glioblastoma.  
 
Conclusion and recommendations 
Selecting the appropriate treatment for an elderly patient with a newly diagnosed 
glioblastoma is challenging and a patient-centred approach is essential. Randomised evidence to 
guide treatment decisions is emerging (table 2) and there is less reason for nihilism. Initial 
consideration should include the appropriateness and extent of surgical intervention. With frailty 
and potential comorbidities there may be increased perioperative complications and prolonged 
recovery; however, maximal safe surgical resection should be considered. Subsequent 
management should incorporate initial symptomatic management including titration of 
corticosteroids and suitable anti-seizure medication if required.  Early introduction of palliative 
care may have a role in many patients. Management should be based upon the fitness of the 
patient, performance status, and MGMT promoter methylation status (Figure 2).
56
 Standard 
radiotherapy of 60Gy in 30 fractions with concurrent and adjuvant TMZ can be utilized for most 
patients under the age of 70 and of appropriate fitness. In patients over the age of 70 there is 
evidence of efficacy for both radiotherapy alone and TMZ monotherapy respectively; the results 
of the NCIC-CTG/EORTC/TROG clinical trial will assess the benefit of hypofractionated 
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radiotherapy with concurrent TMZ compared to radiotherapy alone. Most patients over 70 years 
of age appear not to benefit from conventional radiation schedules such as 60Gy in 30 fractions 
and a hypofractionated schedule is recommended. MGMT may turn out to be even more 
important in the setting of elderly patients than in younger patients in terms of guiding 
management decisions. Ideally MGMT promoter methylation status should be determined on all 
patients 65 years and older. Patients lacking MGMT promoter methylation should be considered 
for a course of hypofractionated radiation therapy alone while those with methylated tumors may 
be offered temozolomide alone. Selection of these treatments requires an interdisciplinary 
discussion of the risks and benefits of RT versus TMZ, incorporation of the patient’s own goals 
of care, and patient preference.  
Some of the current algorithms for elderly glioblastoma patients are based on 
extrapolations from small and underpowered studies, but hopefully over the next few years, 
higher levels of evidence from larger maturing phase III studies will ensure future 
recommendations are more robust. 
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Figure Legends 
Figure 1:  Overall Survival of Glioblastoma Patients Treated in Ontario, Canada Stratified by 
Decade of Age 
Figure 2 Figure 2: Flow diagram of treatment considerations for elderly Glioblastoma patients (a) 
65-70 and (b) >70 
Table Legends 
Table 1:  Average age adjusted incidence per 100,000 and relative survival for GB stratified by age 
(CBTRUS)
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  Table 2:  Randomised clinical evidence for elderly glioblastoma patients. 
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Abstract: 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The median age 
of diagnosis is 64 years, with an increasing number of patients diagnosed over the age of 
seventy. Managing elderly patients with this condition is challenging. Management pathways 
may include surgery, radiotherapy (RT), chemotherapy and best supportive care (BSC). Many 
clinical trials in oncology exclude elderly patients, including some of those for malignant brain 
tumors leaving less evidence to guide treatment in the these patients. Recent advances in 
molecular diagnostics and biomarkers, such as 06-methylguanine-DNA-methyltransferase 
(MGMT) promoter methylation status, may help guide optimal treatment selection. Focusing on 
available randomized data, this review provides a practical overview of the evidence for the 
treatment of newly diagnosed glioblastoma in the elderly including management 
recommendations.  
 
Keywords: Elderly, glioblastoma, surgery, radiotherapy, chemotherapy 
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Convention is to define the ‘elderly’ population as exceeding a specified chronological 
age which varies with temporal, geographical, social and cultural factors. Managing elderly 
patients can be challenging; medical comorbidities, multiple concomitant medications, and 
increasing fragility of health alter drug efficacy and the magnitude and spectrum of adverse 
effects related to treatment. With age, the natural insidious change of physiology and constitution 
affects pharmacokinetic processes with regards to absorption, metabolism, distribution and drug 
clearance.1 Many clinical trials in oncology exclude elderly patients, including some of those for 
malignant brain tumors; as such there is less evidence to guide treatment in the elderly cohort.  
This review provides a practical overview of the evidence for the treatment of newly diagnosed 
glioblastoma in the elderly.  
 
 
Epidemiology 
 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The 
Central Brain Tumour Registry of the United States (CBTRUS) statistical report, which collates 
epidemiological data from over 50 state cancer registries, identified 112,458 malignant primary 
brain and central nervous system (CNS) tumors between 2006 and 2010 of which 45.2% were 
glioblastomas.2 A median age of 64 at diagnosis and an average age-adjusted incidence rate per 
of 3·19 (3·16-3·21) per 100,000 were reported. Stratification by age detected an increase in 
incidence with age, and the peak rate of 14·93 in the 75-84 age range. Of note is the marked 
decrease in survival with advancing age (table 1). The 1-year and 2-year relative survival rates of 
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40·7% and 14·2% for patients aged 55-64 falls to 9·2% and 2·6% for patients aged 75 or older.  
An Ontario (Canada) population-based cohort study of all patients diagnosed with glioblastoma 
between 1982 and 1994 found poorer survival with respect to each increasing decade of age 
(Figure 1 courtesy of Paszat et. al. Unpublished 1999). Whether this poorer survival is a 
reflection of differing provisions of care based on chronological age or reflects more aggressive 
tumor biology, or both, is presently unclear.   
 
The histologic hallmarks of glioblastoma, as defined by the World Health Organization 
(WHO), include cellular polymorphism, nuclear atypia, a high mitotic index, microvascular 
proliferation and necrosis.3 With the emergence of personalized medicine, molecular diagnostics 
are increasingly used to improve the treatment and survival associated with glioblastoma.  
Prognostic biomarkers such as TP53 mutation, 1p deletion, cyclin dependent kinase (CDK) 
N2A/p16 deletion and epidermal growth factor receptor (EGFR) amplification vary with age4. In 
a histological review of 140 patients, TP53 mutations and EGFR amplification had differing 
prognostic significance when stratifying by age, with TP53 mutations being positively prognostic 
for younger patients and negative for older patients (<70yrs 0.84; 95% CI 0.49 –1.42 versus 
>70yrs HR 7.54; 95% CI 2.38–23.87)4. Conversely EGFR amplification in the context of older 
patients was positively prognostic yet in younger patients it was negatively prognostic.4  
 
More recently gene expression-based molecular analysis has been utilized to categorize 
glioblastoma into subtypes including proneural, neural, classical and mesenchymal subtypes.5 
Lee et al. performed a meta-analysis which substantiated the presence of these subtypes, as 
identified by genetic signature and suggested that the prognostic effect of age may in fact be a 
reflection of the differing prevalence of specific subtypes at differing ages; for example the 
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proneural subtype appears to occur more often in younger patients and is associated with longer 
survival.6 Presently these markers do not have a defined role in clinical practice with regards to 
daily management decisions and remain under investigation.  Of note, positive prognostic 
biomarkers, like mutations of isocitrate dehydrogenase (IDH) are virtually absent in 
glioblastoma of the elderly; similarly the general DNA methylation levels in the tumor tissue 
seem to be low. Despite this the frequency of O6-Methylguanine-DNA methyltransferase 
(MGMT) promoter methylation, itself an important positive predictive marker, does not vary 
with age.7 
 
Surgery  
In younger patients, maximal safe resection is advocated with the intent of preserving 
neurological function, providing maximal tissue for molecular profiling, and improving overall 
survival. Analysis of the extent of surgery in Radiation Therapy Oncology Group (RTOG) 
randomised trials, found significant improvement in survival with partial/total resection versus 
biopsy alone.8 Review of an unselected population of 345 newly diagnosed glioblastoma patients 
from the German Glioma Network (GGN) demonstrated gross tumour resection to be associated 
with superior overall survival (OS) (median 17·1 months) compared to incomplete resection 
(median 11·7 months) and biopsy alone (median 8·7 months).9 A multivariate analysis of 416 
glioblastoma patients treated at a single institution between 1993 and 1999 reported resections of 
tumour volume in the order of 98% or greater to be associated with significant survival 
advantage (median survival 13 months, 95% CI 11·4–14·6 months versus 8·8 months (95% CI 
7·4–10·2 months; p < 0·0001).10  
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There is one randomized trial pertaining to surgical intervention, including elderly 
patients with glioblastoma. This small study of 30 patients assessed the role of debulking surgery 
compared to biopsy alone.11  Patients aged 65 or older with KPS >60 were randomized to open 
craniotomy and resection [14 patients with a median age of 70 (66-80)] or stereotactic biopsy [16 
patients with a median of age 72 (67 -79)]. Surgical resection resulted in superior overall survival 
(171 days (95% CI 146–278) vs. 85 days (95% CI 55–157) p = 0·0346). More recently, a case-
control study with a subgroup analysis of 52 patients aged 70 or over found a median survival of 
4·5 months and 3 months for surgical resection and needle biopsy respectively (p = 0·03).12 
Perhaps the most relevant trial for the topic is the Neuro-oncology Working Group of the 
German Cancer Society NOA-08 study which found extent of surgery to be an independent 
prognostic factor for overall survival among glioblastoma patients 65 years and older.13 
Furthermore, multivariate analysis of all patients (n=342) participating in the Nordic trial of 
standard vs. hypofractionated radiotherapy vs. chemotherapy alone in newly diagnosed 
glioblastoma patients 65 years of age or older also demonstrated a survival benefit favoring 
surgery over biopsy alone (biopsy versus resection HR 1·50 (1·17 -1·92) p =0·001).14 
 
Standard post-operative management for newly diagnosed glioblastoma 
The European Organisation for Research and Treatment of Cancer (EORTC) 26981-
22981/National Cancer Institute of Canada Clinical Trials Group (NCIC) CE.3 randomised phase 
III trial assessed the addition of temozolomide (TMZ) to radiotherapy (RT) in the concomitant 
and sequential adjuvant setting in glioblastoma patients aged 18-70.15  Median age was 56 (range 
19-71) and the selected population required Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–2. The addition of TMZ resulted in a median survival benefit of 2·5 
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months; 14·6 months (95% CI 13·2- 16·8) compared with 12·1 months (95%CI 11·2 -13·0) for 
radiotherapy alone. The 5-year analysis of this trial confirmed a persisting advantage and this has 
become the standard of care post-surgical resection for patients less than 70 years of age and of 
appropriate performance status.16 In a recent review Laperriere et. al. noted that subgroup 
analysis of this trial demonstrated a trend to benefit in the more elderly subgroups, albeit with a 
less impressive hazard ratio and without reaching statistical significance. Specifically, there was 
diminishing benefit of combined treatment with increasing age (61-65 years: HR 0.64 p = 0.096 
and 66–70 years: HR = 0·78 p = 0·34) compared to the overall group (HR 0·6, 95%CI 0·5-0·7; 
p<0·0001).17 This may reflect less robust effects of the combined approach in the elderly or may 
be due to lower statistical power in the subgroup analysis. 
 
Radiation for elderly patients 
Randomized trials have long demonstrated a survival benefit from post-operative 
radiotherapy in the management of glioblastoma and more recently several trials have focused on 
the elderly. The French ANOCEF group found a median survival benefit of 12.2 weeks in favour 
of RT plus best supportive care (BSC) versus BSC alone.18 Patients aged 70 or older with a KPS 
>70 and a diagnosis of glioblastoma or anaplastic astrocytoma were randomized postoperatively 
to receive BSC [(42 patients (median age 73; range 70-85)] or BSC and 50 Gy in 1.8 Gy 
fractions to a clinical target volume (CTV) consisting of enhancing tumour with a 2cm margin 
[(39 patients (median age 75; range 70-84)]. Overall survival was 16·9 (95% CI, 13·4 to 21·4) 
and 29·1 weeks (95% CI, 25·4 to 34·9) respectively. No significant difference was detected with 
regards to quality of life; however, Health Related Quality of Life (HRQoL) assessments were 
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incomplete.  Cox proportional hazard modelling revealed that extent of surgery was associated 
with increased survival.  
Scott et al. performed a large retrospective review of elderly glioblastoma patients 
diagnosed between 1993 and 2005.19 The study sample of 2836 patients identified from the 
Surveillance, Epidemiology, and End Results (SEER) registry database had a median age of 76·9 
years (range 71·0–98·0). Kaplan-Meier analysis revealed median cancer-specific survivals of 8 
months for patients undergoing both surgery and postoperative radiotherapy, 4 months for 
radiation alone, 3 months for surgery alone and 2 months for neither surgery nor radiotherapy 
(log rank p<0·001). Multivariate analysis suggested radiotherapy significantly increased cancer-
specific survival after adjusting for tumour size, tumour location, surgery and patient 
demographics with a hazard ratio (HR) of 0·43 (95% CI, 0·38–0·49). 19 
The biological effect of radiation on tumour and normal tissues is dependent upon the 
provision of dose over time as well as intrinsic radio-sensitivity (α) and repair capability (ß). 
Glioblastoma has an alpha-beta ratio (α/ ß) = 8Gy (5·0–10·8)20 which is in the range of most 
tumours, while the alpha-beta ratio is approximately 2 for the normal central nervous system. As 
a result of this difference, hypofractionation reduces overall treatment time and may minimize 
the potential for tumor cell repopulation and provides a practical convenience for an elderly frail 
population. Roa et. al. randomized patients aged 60 or older to radiotherapy given as 60Gy in 30 
fractions (47 patients, mean age 72.4 yrs, SD 5·4) or a hypofractionated regimen of 40Gy in 15 
fractions (48 patients, mean 71·0 yrs, SD 5·5).21 While this study was not sufficiently powered to 
conclude equivalence of these two fractionation schedules it suggested no significant differences 
in OS [median 5.1 months for the standard RT arm versus 5·6 months for the shorter course (log 
rank p = 0·57)], survival at 6 months (44·7% standard RT versus 41·7% hypofractionated RT), 
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or HRQoL.  More patients required an increase of corticosteroid dose following the standard 
radiotherapy schedule compared to the hypofractionated course (p= 0·02). 
The Nordic trial incorporated a different hypofractionated radiotherapy schedule.14 There 
were 3 treatment arms including standard radiotherapy of 60Gy in 30 fractions, hypofractionated 
radiotherapy of 34Gy in 10 fractions or temozolomide 200mg/m2 days 1-5 every 28 days for up 
to 6 cycles. Standard radiotherapy (60Gy/30) was not routinely offered to elderly patients in 
some study sites so randomization between just the hypofractionated radiotherapy and 
temozolomide arms was permitted.  Two hundred and ninety one glioblastoma patients (initially 
aged 60 years or older then in view of EORTC 26981-22981/NCIC-CTG CE.3 the age eligibility 
was adjusted so that patients 60-65 years old fit for combined treatment were excluded) were 
randomized to standard radiotherapy (n=100), hypofractionated radiotherapy (n=98) or 
temozolomide alone (n=93). A further 51 patients were randomized to either hypofractionated 
radiotherapy (n=25) or TMZ (n=26) by those centers that did not offer 60Gy in 30 fractions as 
their standard care. 
The median age was 70 for both the hypofractionated and the standard radiotherapy 
groups. Median survival in the hypofractionated group was increased by 1·5 months compared to 
standard radiation in the three-arm comparison. Interestingly, on stratification by age, the 
advantage of hypofractionated radiation appeared better in patients over the age of 70 (7·0 (5·2–
8·8) versus 5·2 (4·0–6·3) months). Treatment completion according to protocol was more 
frequent with the hypofractionated schedule (95% versus 72%). Salvage treatment was received 
for a similar proportion of patients in both groups while reported toxicity was not different 
between groups.   
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Temozolomide and O-6-methylguanine-DNA methyltransferase  
The alkylating agent TMZ has activity in glioblastoma, and in combination with 
radiotherapy followed sequentially by a 6 month maintenance course represents the current 
standard of care for many patients. The mechanism of anti-tumour activity is believed to arise 
through methylation of DNA at the O-6 position of guanine by monomethyl-triazeno-imidazole-
carboxyamide (MTIC), a non-enzymatic chemical degradation product of temozolomide.22     
MGMT is a DNA repair protein implicated in resistance to alkylating agents.23  
Methylation of the MGMT promoter, located at 10q26, leads to suppression of MGMT gene 
expression and an increased likelihood of clinical benefit.23-25 Hegi et al. assessed the MGMT 
promoter methylation status of patients randomized in the EORTC trial 26981/ NCIC CE.3 
trial.25 Regardless of treatment arm, OS was longer in patients with MGMT promoter 
methylation; 18.2 months compared with 12.2 months [HR for death 0·45 (95% CI 0·32 - 0·61)]. 
The magnitude of this effect was more substantial for patients receiving TMZ compared with 
those receiving radiation alone (P=0·007 vs. P=0·06, log-rank test). Of note, the majority of 
patients allocated to radiotherapy alone received alkylating agent chemotherapy as salvage 
treatment further supporting the use of concomitant therapy ‘upfront’ in newly diagnosed 
patients.25 The prognostic significance of MGMT promoter methylation status was prospectively 
corroborated in the RTOG 0525 randomized study of TMZ dose density in the adjuvant setting. 
In this study, dose-dense TMZ (n=422) failed to demonstrate a survival advantage over standard 
dosing (n=411).26 The absence of a TMZ-free control arm did not allow distinction between 
prognostic and predictive properties. 
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For elderly patients not suitable for the combined modality approach, recent evidence 
supports consideration of TMZ alone particularly for tumors harbouring MGMT promoter 
methylation.27 Temozolomide alone was assessed in the Nordic study,14 which found longer 
survival for both TMZ alone and hypofractionated radiotherapy over standard radiotherapy in 
patients older than 65 years of age. Comparison of TMZ and hypofractionated radiotherapy 
revealed no significant difference in overall survival (7·4 versus 8·4 months HR 0·82 95%CI 
0·63-1·06). In the head to head comparison of TMZ versus hypofractionated radiation, 36% of 
the TMZ recipients had subsequent radiation and 29% of the hypofractionated group had salvage 
chemotherapy. MGMT promoter methylation status was available in 258 (75%) of 342 patients. 
Patients with MGMT promoter methylated tumors receiving TMZ survived 2.9 months longer 
than those with unmethylated tumors (HR 0·56, 95% CI 0·34-0·93, p=0·02). No survival 
advantage was identified based on MGMT promoter methylation status within the cohort 
receiving radiation (HR 0·97, 95% CI 0·69-1·38, p=0·81). Although the intent for the TMZ 
group was to complete six cycles, at least two cycles were administered to 86% of patients, and 
only 34% completed all six cycles. Haematological toxicity as well as nausea and vomiting were 
more frequent as would be expected in the TMZ cohort. In addition, a treatment-related death 
involving thrombocytopenia highlights that prescribing chemotherapy is not without the potential 
for serious toxicity. 
 
In the NOA-08 study,13 192 patients received TMZ (1 week on, 1 week off schedule 100 
mg/m2 days 1–7) and 178 patients received 60Gy radiotherapy alone over 6–7 weeks to the 
gross tumour volume (GTV) + 2 centimeters. Median overall survival was similar for the two 
treatment arms: 8·6 months in the TMZ group and 9·6 months in the radiotherapy group (HR 
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1·09, 95% CI 0·84–1·42, p non-inferiority=0·033). MGMT promoter methylation status was 
available in 55% of patients receiving TMZ and 57% of patients receiving radiation with a 
predictive benefit seen for patients receiving the alkylating agent in the context of MGMT 
promoter methylated tumors. Hematological toxicity, abnormal liver function tests, infections 
and thromboembolic events were more prevalent in the TMZ group.  
 
These trials found that MGMT promoter methylation is a predictive biomarker of benefit 
from TMZ, but not radiotherapy. The randomized international NCIC/EORTC/TROG study, 
which completed accrual in September 2013 (JP, personal communication), aims to address the 
potential benefit of combining short course radiotherapy (40Gy in 15 fractions) with concurrent 
and adjuvant TMZ in patients over 65 years who have had prior surgery/biopsy at diagnosis and 
are not deemed suitable for the standard radiotherapy regimen of 60Gy.28 MGMT status will be 
assessed in this study. 
A phase 2 ANOCEF study suggests that older age and poor KPS should not preclude the 
use of TMZ alone.29 This was a non-randomized study which recruited 70 patients with a median 
age of 77 (range 70-87) and a median KPS of 60 (range 30-60). Intriguingly this study found an 
improvement of KPS in excess of 10 for 23 (33%) of treated patients with 18 (26%) having a rise 
to 70 or more. A maximum of 12 cycles of TMZ was planned however the median number of 
cycles received was only 2 with 20% and 24% of patients having dose delays and dose 
reductions for hematological toxicity respectively. Grade 3 or 4 hematological toxicities were not 
insignificant with 13% experiencing grade 3-4 neutropenia and 14% grade 3-4 
thrombocytopenia. No deaths were attributed to treatment. Although only 44% of patients were 
able to have tumor material assessed for MGMT promoter methylation, this study again 
14 
 
demonstrated its predictive role with a hazard ratio for death of 2.307(95% CI 1.073 to 4.962) for 
patients with unmethylated MGMT promoter status (P=0·03). This phase II study introduces the 
question – should more elderly patients with poor performance status be primarily treated with 
TMZ monotherapy? Or should TMZ monotherapy be employed only in those whose tumor 
harbors a methylated MGMT promoter?    
Although MGMT promoter methylation status is increasingly available it still not used in 
all centres. In the future increasing evidence favoring MGMT testing is likely to demand more 
widespread availability; for example the European Association for Neuro-Oncology (EANO) 
guideline for the diagnosis and treatment of malignant gliomas has already declared that MGMT 
promoter methylation status testing is standard of care30.  There have been some controversies 
regarding the methodology of MGMT testing, with some centers preferring pyrosequencing and 
others utilizing PCR. Immunohistochemistical assessment of MGMT does not appear to correlate 
with overall survival.31 
 
Bevacizumab 
Three uncontrolled studies indicate that the vascular endothelial growth factor (VEGF) 
antibody bevacizumab may have increased activity in elderly patients with glioblastoma.32-34 In 
2014, the efficacy of bevacizumab in newly diagnosed glioblastoma patients has been reported 
by two large, placebo-controlled, randomized trials.35,36 The Avastin in Glioblastoma (AVAglio) 
phase III study evaluated the effect of the addition of bevacizumab to focal radiotherapy with 
concurrent TMZ, to the adjuvant component and then beyond the adjuvant component until 
progression.34 Although improved progression-free survival (HR 0·65 (0·56–0·75)), preservation 
of baseline quality of life and performance status were reported, there was no improvement in 
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overall survival. Stratified by age over 70 years, the statistical significance with regards to PFS 
was lost [HR 0·78 (0·46–1·33)]; however this may reflect an issue of statistical power and small 
subgroups rather than a lack of clinical efficacy.  The RTOG 0825 trial, sharing a similar design, 
also failed to demonstrate an overall survival benefit35 but in contrast to the AVAglio study, a 
greater deterioration clinically assessed by patient reported outcome questionnaire, was evident 
in the bevacizumab group. There were differences in the design of these two studies that may 
influence determination of progression and patient reports outcomes.  Radiological assessment in 
the RTOG 0825 study was by serial measurement of cross-sectional diameter and use of the 
international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)37 
committee whereas the AVAglio study utilized an adaptation of the Macdonald criteria, similar 
to the newer RANO criteria, which takes into account the issues of pseudoprogression, 
pseudoresponse and changes in the non-enhancing disease.38  Ongoing discussion and analyses 
may further clarify the apparent discordant results with regard to progression-free survival  in 
these two pivotal trials.  
 No clinical or tissue based biomarkers have yet been prospectively shown to be 
associated with benefit from bevacizumab although patients with glioblastomas harbouring a 
proneural subtype may derive the most benefit.39 At present bevacizumab has no role in the 
standard upfront treatment of glioblastoma; however, future clinical trials may attempt to target 
specific groups of patients defined by sets of biomarkers. The randomized Avastin plus 
Radiotherapy in Elderly Patients with Glioblastoma (ARTE) study, a phase II trial, will explore 
whether the addition of bevacizumab to radiotherapy improves outcome in elderly patients with 
newly diagnosed glioblastoma without MGMT promoter methylation (M. Weller, personal 
communication). 
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Symptomatic management  
Glioblastoma can cause many difficult symptoms ranging from fatigue to those 
associated with raised intracranial pressure. Seizures may often occur as well as cognitive, motor 
or sensory deficits occurring in a location-dependent manner. Corticosteroids are often required 
to control symptoms of cerebral edema and their utility over time must be balanced with 
potential side effects such as proximal myopathy, steroid-induced diabetes, and osteoporotic 
fractures which can be debilitating. Furthermore, corticosteroids may reduce the benefit from 
TMZ in the most promising MGMT promoter methylated subgroup.40 Anti-seizure medications 
are also often warranted.  There is no randomised evidence pertaining to palliative care in the 
glioblastoma setting. However, based on a randomised study in non-small lung cancer, which 
demonstrated the addition of palliative care not only improved quality of life but also increased 
overall survival, many would advocate the early incorporation of palliative care support.41  
 
Population-based retrospective studies 
For glioblastoma, like many other cancers, results from randomized clinical trials (RCTs) 
may not reflect ‘real world” outcomes as described in population based studies. Several large 
population based studies have shown that many elderly patients do not receive the ‘gold 
standard’ treatment.  For example, despite the increasing body of evidence regarding the 
important benefit of resection rather than biopsy, numerous international pattern of care 
studies42-46 demonstrate a much higher rate of biopsy alone rather than attempted resection in the 
elderly population. 
The SEER database study published by Scott et. al. reported that among 2836 patients, 
only 46% of those over the age of 70 received both surgery and radiotherapy, with omission of 
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treatment associated with poorer survival.19 A similar SEER study of 4,137 patients with 
glioblastoma, aged 65 or older, reported a median overall survival of 4 months and described age 
to be associated with lower odds of resection and provision of RT or chemotherapy.19 The 
Princess Margaret Cancer Centre published outcomes of 131 patients aged greater than 70 
treated in the ‘temozolomide era’ between 2004 and 2008.47  Elderly patients were more likely to 
receive best supportive care or ‘palliative’ doses of radiotherapy with only 1 patient receiving 
60Gy in 30 fractions in combination with TMZ. Only 6 patients (5%) received TMZ post-
radiation, with only a median of 2.5 cycles administered.  A retrospective review of 235 patients 
aged 65 or over treated between 2006 and 2013 at the Odette Cancer Center in Toronto provides 
a more contemporary overview regarding provision of care in the elderly setting.48 With a 
median survival of approximately 2 months, 19% of patients were deemed not suitable for active 
treatment. 
There is a likely another subgroup of elderly patients not reflected in statistics who might 
be presumptively diagnosed on radiological investigations (e.g. imaging for suspected stroke) but 
for various reasons (e.g. comorbidities, patient and family preference) do not proceed even to a 
biopsy. Of course, in certain scenarios, e.g. bedbound patient with dementia, it may be 
inappropriate to pursue active management. 
Survivorship in the ‘real world’ would appear less favorable to that quoted in RCTs and 
may be a reflection of both physician preference to not to administer treatment in a group 
previously not studied as well as patient choice. The definition of ‘elderly’ varies across clinical 
trials and may appear to limit the ability to cross-compare data from these studies. That said, the 
NOA-08 trial had a median age of 72 (66-84) years in the TMZ arm and 72 (66-82) years in the 
RT arm. Age as a continuous variable or dichotomized at age 70 was not an independent 
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prognostic factor for either OS or event-free survival13; thus the association with age may not be 
as important in patients older than 70 years. Patients from population-based studies are clearly 
different that those included in the randomized trials. A patient-centered approach is important, 
as in all aspects of medicine, and treatment decisions need to involve a patient’s own preferences 
and goals of care should be a focus early in the discussion regarding management.   
 
Practical aspects: 
Practical considerations such as performance status and even the ability of the patient to 
get to appointments can also come into play, as many of these patients are no longer driving. For 
example, a mobile elderly patient with a poor short-term memory, but with a strong family 
network advocating for active treatment, is far more likely to be treated than a socially isolated 
patient. If a cognitively intact patient with poor mobility is keen for treatment; again the presence 
of supportive family will often make a difference impacting on decision-making. 
Often rehabilitation is not offered for glioblastoma patients postoperatively. However, 
there is evidence that postoperative rehabilitation in this setting is just as useful as in the stroke 
setting49,50 and should be considered where possible. There are observational studies which show 
improvement in patients’ functional status during the course of rehabilitation therapy, including 
the functional independence measure (FIM)51,52 and referral for rehabilitation is advocated.53 
Elderly patients and their caregivers may have numerous symptoms or challenges ahead. 
Challenges include treatment and tumor-related symptoms and deficits, seizures, headaches, 
communication difficulties (e.g. expressive or receptive aphasia), personality and behaviour 
changes (e.g. frontal syndrome with disinhibition and emotional lability), poor concentration, 
poor memory, fatigue, weakness, mobility; hemiparesis, impaired judgement/insight and 
19 
 
depression (reactive versus major). These challenges can be even more difficult to manage in the 
setting of comorbidities and polypharmacy often faced by elderly patients. 
The clinical journey is a complex one and can involve interaction with many health 
professionals- including neurosurgeon, radiation oncologist (and radiation therapists), medical 
oncologist, palliative care physician, occupational therapist, physiotherapist, neurologist, 
endocrinologist (for steroid-induced diabetes) or diabetic educator, social worker, pharmacist, 
psychologist, speech pathologist etc. and ideally a cancer care coordinator should be available, 
where possible, to help the patient navigate through this difficult pathway. 
Caregiver burnout is also very important for clinicians to be aware of. Recent studies 
have demonstrated that the global quality of life is often poorer in the caregiver than in the 
patients themselves.54,55 Often, in the elderly setting, a spouse (if there is one) has their own co-
morbidities to deal with and struggles to manage both physically and emotionally with the 
complexities involved with caring for a partner with glioblastoma.  
 
Conclusion and recommendations 
Selecting the appropriate treatment for an elderly patient with a newly diagnosed 
glioblastoma is challenging and a patient-centred approach is essential. Randomised evidence to 
guide treatment decisions is emerging (table 2) and there is less reason for nihilism. Initial 
consideration should include the appropriateness and extent of surgical intervention. With frailty 
and potential comorbidities there may be increased perioperative complications and prolonged 
recovery; however, maximal safe surgical resection should be considered. Subsequent 
management should incorporate initial symptomatic management including titration of 
corticosteroids and suitable anti-seizure medication if required.  Early introduction of palliative 
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care may have a role in many patients. Management should be based upon the fitness of the 
patient, performance status, and MGMT promoter methylation status (Figure 2).56 Standard 
radiotherapy of 60Gy in 30 fractions with concurrent and adjuvant TMZ can be utilized for most 
patients under the age of 70 and of appropriate fitness. In patients over the age of 70 there is 
evidence of efficacy for both radiotherapy alone and TMZ monotherapy respectively; the results 
of the NCIC-CTG/EORTC/TROG clinical trial will assess the benefit of hypofractionated 
radiotherapy with concurrent TMZ compared to radiotherapy alone. Most patients over 70 years 
of age appear not to benefit from conventional radiation schedules such as 60Gy in 30 fractions 
and a hypofractionated schedule is recommended. MGMT may turn out to be even more 
important in the setting of elderly patients than in younger patients in terms of guiding 
management decisions. Ideally MGMT promoter methylation status should be determined on all 
patients 65 years and older. Patients lacking MGMT promoter methylation should be considered 
for a course of hypofractionated radiation therapy alone while those with methylated tumors may 
be offered temozolomide alone. Selection of these treatments requires an interdisciplinary 
discussion of the risks and benefits of RT versus TMZ, incorporation of the patient’s own goals 
of care, and patient preference.  
Some of the current algorithms for elderly glioblastoma patients are based on 
extrapolations from small and underpowered studies, but hopefully over the next few years, 
higher levels of evidence from larger maturing phase III studies will ensure future 
recommendations are more robust. 
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Figure 1:  Overall Survival of Glioblastoma Patients Treated in Ontario, Canada Stratified by 
Decade of Age 
Figure 2 Figure 2: Flow diagram of treatment considerations for elderly Glioblastoma patients (a) 
65-70 and (b) >70 
Table Legends 
Table 1:  Average age adjusted incidence per 100,000 and relative survival for GB stratified by age 
(CBTRUS)2 
  Table 2:  Randomised clinical evidence for elderly glioblastoma patients. 
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Abstract: 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The median age 
of diagnosis is 64 years, with an increasing number of patients diagnosed over the age of 
seventy. Managing elderly patients with this condition is challenging. Management pathways 
may include surgery, radiotherapy (RT), chemotherapy and best supportive care (BSC). Many 
clinical trials in oncology exclude elderly patients, including some of those for malignant brain 
tumors leaving less evidence to guide treatment in the these patients. Recent advances in 
molecular diagnostics and biomarkers, such as 06-methylguanine-DNA-methyltransferase 
(MGMT) promoter methylation status, may help guide optimal treatment selection. Focusing on 
available randomized data, this review provides a practical overview of the evidence for the 
treatment of newly diagnosed glioblastoma in the elderly including management 
recommendations.  
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Convention is to define the ‘elderly’ population as exceeding a specified chronological 
age which varies with temporal, geographical, social and cultural factors. Managing elderly 
patients can be challenging; medical comorbidities, multiple concomitant medications, and 
increasing fragility of health alter drug efficacy and the magnitude and spectrum of adverse 
effects related to treatment. With age, the natural insidious change of physiology and constitution 
affects pharmacokinetic processes with regards to absorption, metabolism, distribution and drug 
clearance.1 Many clinical trials in oncology exclude elderly patients, including some of those for 
malignant brain tumors; as such there is less evidence to guide treatment in the elderly cohort.  
This review provides a practical overview of the evidence for the treatment of newly diagnosed 
glioblastoma in the elderly.  
 
 
Epidemiology 
 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The 
Central Brain Tumour Registry of the United States (CBTRUS) statistical report, which collates 
epidemiological data from over 50 state cancer registries, identified 112,458 malignant primary 
brain and central nervous system (CNS) tumors between 2006 and 2010 of which 45.2% were 
glioblastomas.2 A median age of 64 at diagnosis and an average age-adjusted incidence rate per 
of 3·19 (3·16-3·21) per 100,000 were reported. Stratification by age detected an increase in 
incidence with age, and the peak rate of 14·93 in the 75-84 age range. Of note is the marked 
decrease in survival with advancing age (table 1). The 1-year and 2-year relative survival rates of 
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40·7% and 14·2% for patients aged 55-64 falls to 9·2% and 2·6% for patients aged 75 or older.  
An Ontario (Canada) population-based cohort study of all patients diagnosed with glioblastoma 
between 1982 and 1994 found poorer survival with respect to each increasing decade of age 
(Figure 1 courtesy of Paszat et. al. Unpublished 1999). Whether this poorer survival is a 
reflection of differing provisions of care based on chronological age or reflects more aggressive 
tumor biology, or both, is presently unclear.   
 
The histologic hallmarks of glioblastoma, as defined by the World Health Organization 
(WHO), include cellular polymorphism, nuclear atypia, a high mitotic index, microvascular 
proliferation and necrosis.3 With the emergence of personalized medicine, molecular diagnostics 
are increasingly used to improve the treatment and survival associated with glioblastoma.  
Prognostic biomarkers such as TP53 mutation, 1p deletion, cyclin dependent kinase (CDK) 
N2A/p16 deletion and epidermal growth factor receptor (EGFR) amplification vary with age4. In 
a histological review of 140 patients, TP53 mutations and EGFR amplification had differing 
prognostic significance when stratifying by age, with TP53 mutations being positively prognostic 
for younger patients and negative for older patients (<70yrs 0.84; 95% CI 0.49 –1.42 versus 
>70yrs HR 7.54; 95% CI 2.38–23.87)4. Conversely EGFR amplification in the context of older 
patients was positively prognostic yet in younger patients it was negatively prognostic.4  
 
More recently gene expression-based molecular analysis has been utilized to categorize 
glioblastoma into subtypes including proneural, neural, classical and mesenchymal subtypes.5 
Lee et al. performed a meta-analysis which substantiated the presence of these subtypes, as 
identified by genetic signature and suggested that the prognostic effect of age may in fact be a 
reflection of the differing prevalence of specific subtypes at differing ages; for example the 
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proneural subtype appears to occur more often in younger patients and is associated with longer 
survival.6 Presently these markers do not have a defined role in clinical practice with regards to 
daily management decisions and remain under investigation.  Of note, positive prognostic 
biomarkers, like mutations of isocitrate dehydrogenase (IDH) are virtually absent in 
glioblastoma of the elderly; similarly the general DNA methylation levels in the tumor tissue 
seem to be low. Despite this the frequency of O6-Methylguanine-DNA methyltransferase 
(MGMT) promoter methylation, itself an important positive predictive marker, does not vary 
with age.7 
 
Surgery  
In younger patients, maximal safe resection is advocated with the intent of preserving 
neurological function, providing maximal tissue for molecular profiling, and improving overall 
survival. Analysis of the extent of surgery in Radiation Therapy Oncology Group (RTOG) 
randomised trials, found significant improvement in survival with partial/total resection versus 
biopsy alone.8 Review of an unselected population of 345 newly diagnosed glioblastoma patients 
from the German Glioma Network (GGN) demonstrated gross tumour resection to be associated 
with superior overall survival (OS) (median 17·1 months) compared to incomplete resection 
(median 11·7 months) and biopsy alone (median 8·7 months).9 A multivariate analysis of 416 
glioblastoma patients treated at a single institution between 1993 and 1999 reported resections of 
tumour volume in the order of 98% or greater to be associated with significant survival 
advantage (median survival 13 months, 95% CI 11·4–14·6 months versus 8·8 months (95% CI 
7·4–10·2 months; p < 0·0001).10  
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There is one randomized trial pertaining to surgical intervention, including elderly 
patients with glioblastoma. This small study of 30 patients assessed the role of debulking surgery 
compared to biopsy alone.11  Patients aged 65 or older with KPS >60 were randomized to open 
craniotomy and resection [14 patients with a median age of 70 (66-80)] or stereotactic biopsy [16 
patients with a median of age 72 (67 -79)]. Surgical resection resulted in superior overall survival 
(171 days (95% CI 146–278) vs. 85 days (95% CI 55–157) p = 0·0346). More recently, a case-
control study with a subgroup analysis of 52 patients aged 70 or over found a median survival of 
4·5 months and 3 months for surgical resection and needle biopsy respectively (p = 0·03).12 
Perhaps the most relevant trial for the topic is the Neuro-oncology Working Group of the 
German Cancer Society NOA-08 study which found extent of surgery to be an independent 
prognostic factor for overall survival among glioblastoma patients 65 years and older.13 
Furthermore, multivariate analysis of all patients (n=342) participating in the Nordic trial of 
standard vs. hypofractionated radiotherapy vs. chemotherapy alone in newly diagnosed 
glioblastoma patients 65 years of age or older also demonstrated a survival benefit favoring 
surgery over biopsy alone (biopsy versus resection HR 1·50 (1·17 -1·92) p =0·001).14 
 
Standard post-operative management for newly diagnosed glioblastoma 
The European Organisation for Research and Treatment of Cancer (EORTC) 26981-
22981/National Cancer Institute of Canada Clinical Trials Group (NCIC) CE.3 randomised phase 
III trial assessed the addition of temozolomide (TMZ) to radiotherapy (RT) in the concomitant 
and sequential adjuvant setting in glioblastoma patients aged 18-70.15  Median age was 56 (range 
19-71) and the selected population required Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–2. The addition of TMZ resulted in a median survival benefit of 2·5 
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months; 14·6 months (95% CI 13·2- 16·8) compared with 12·1 months (95%CI 11·2 -13·0) for 
radiotherapy alone. The 5-year analysis of this trial confirmed a persisting advantage and this has 
become the standard of care post-surgical resection for patients less than 70 years of age and of 
appropriate performance status.16 In a recent review Laperriere et. al. noted that subgroup 
analysis of this trial demonstrated a trend to benefit in the more elderly subgroups, albeit with a 
less impressive hazard ratio and without reaching statistical significance. Specifically, there was 
diminishing benefit of combined treatment with increasing age (61-65 years: HR 0.64 p = 0.096 
and 66–70 years: HR = 0·78 p = 0·34) compared to the overall group (HR 0·6, 95%CI 0·5-0·7; 
p<0·0001).17 This may reflect less robust effects of the combined approach in the elderly or may 
be due to lower statistical power in the subgroup analysis. 
 
Radiation for elderly patients 
Randomized trials have long demonstrated a survival benefit from post-operative 
radiotherapy in the management of glioblastoma and more recently several trials have focused on 
the elderly. The French ANOCEF group found a median survival benefit of 12.2 weeks in favour 
of RT plus best supportive care (BSC) versus BSC alone.18 Patients aged 70 or older with a KPS 
>70 and a diagnosis of glioblastoma or anaplastic astrocytoma were randomized postoperatively 
to receive BSC [(42 patients (median age 73; range 70-85)] or BSC and 50 Gy in 1.8 Gy 
fractions to a clinical target volume (CTV) consisting of enhancing tumour with a 2cm margin 
[(39 patients (median age 75; range 70-84)]. Overall survival was 16·9 (95% CI, 13·4 to 21·4) 
and 29·1 weeks (95% CI, 25·4 to 34·9) respectively. No significant difference was detected with 
regards to quality of life; however, Health Related Quality of Life (HRQoL) assessments were 
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incomplete.  Cox proportional hazard modelling revealed that extent of surgery was associated 
with increased survival.  
Scott et al. performed a large retrospective review of elderly glioblastoma patients 
diagnosed between 1993 and 2005.19 The study sample of 2836 patients identified from the 
Surveillance, Epidemiology, and End Results (SEER) registry database had a median age of 76·9 
years (range 71·0–98·0). Kaplan-Meier analysis revealed median cancer-specific survivals of 8 
months for patients undergoing both surgery and postoperative radiotherapy, 4 months for 
radiation alone, 3 months for surgery alone and 2 months for neither surgery nor radiotherapy 
(log rank p<0·001). Multivariate analysis suggested radiotherapy significantly increased cancer-
specific survival after adjusting for tumour size, tumour location, surgery and patient 
demographics with a hazard ratio (HR) of 0·43 (95% CI, 0·38–0·49). 19 
The biological effect of radiation on tumour and normal tissues is dependent upon the 
provision of dose over time as well as intrinsic radio-sensitivity (α) and repair capability (ß). 
Glioblastoma has an alpha-beta ratio (α/ ß) = 8Gy (5·0–10·8)20 which is in the range of most 
tumours, while the alpha-beta ratio is approximately 2 for the normal central nervous system. As 
a result of this difference, hypofractionation reduces overall treatment time and may minimize 
the potential for tumor cell repopulation and provides a practical convenience for an elderly frail 
population. Roa et. al. randomized patients aged 60 or older to radiotherapy given as 60Gy in 30 
fractions (47 patients, mean age 72.4 yrs, SD 5·4) or a hypofractionated regimen of 40Gy in 15 
fractions (48 patients, mean 71·0 yrs, SD 5·5).21 While this study was not sufficiently powered to 
conclude equivalence of these two fractionation schedules it suggested no significant differences 
in OS [median 5.1 months for the standard RT arm versus 5·6 months for the shorter course (log 
rank p = 0·57)], survival at 6 months (44·7% standard RT versus 41·7% hypofractionated RT), 
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or HRQoL.  More patients required an increase of corticosteroid dose following the standard 
radiotherapy schedule compared to the hypofractionated course (p= 0·02). 
The Nordic trial incorporated a different hypofractionated radiotherapy schedule.14 There 
were 3 treatment arms including standard radiotherapy of 60Gy in 30 fractions, hypofractionated 
radiotherapy of 34Gy in 10 fractions or temozolomide 200mg/m2 days 1-5 every 28 days for up 
to 6 cycles. Standard radiotherapy (60Gy/30) was not routinely offered to elderly patients in 
some study sites so randomization between just the hypofractionated radiotherapy and 
temozolomide arms was permitted.  Two hundred and ninety one glioblastoma patients (initially 
aged 60 years or older then in view of EORTC 26981-22981/NCIC-CTG CE.3 the age eligibility 
was adjusted so that patients 60-65 years old fit for combined treatment were excluded) were 
randomized to standard radiotherapy (n=100), hypofractionated radiotherapy (n=98) or 
temozolomide alone (n=93). A further 51 patients were randomized to either hypofractionated 
radiotherapy (n=25) or TMZ (n=26) by those centers that did not offer 60Gy in 30 fractions as 
their standard care. 
The median age was 70 for both the hypofractionated and the standard radiotherapy 
groups. Median survival in the hypofractionated group was increased by 1·5 months compared to 
standard radiation in the three-arm comparison. Interestingly, on stratification by age, the 
advantage of hypofractionated radiation appeared better in patients over the age of 70 (7·0 (5·2–
8·8) versus 5·2 (4·0–6·3) months). Treatment completion according to protocol was more 
frequent with the hypofractionated schedule (95% versus 72%). Salvage treatment was received 
for a similar proportion of patients in both groups while reported toxicity was not different 
between groups.   
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Temozolomide and O-6-methylguanine-DNA methyltransferase  
The alkylating agent TMZ has activity in glioblastoma, and in combination with 
radiotherapy followed sequentially by a 6 month maintenance course represents the current 
standard of care for many patients. The mechanism of anti-tumour activity is believed to arise 
through methylation of DNA at the O-6 position of guanine by monomethyl-triazeno-imidazole-
carboxyamide (MTIC), a non-enzymatic chemical degradation product of temozolomide.22     
MGMT is a DNA repair protein implicated in resistance to alkylating agents.23  
Methylation of the MGMT promoter, located at 10q26, leads to suppression of MGMT gene 
expression and an increased likelihood of clinical benefit.23-25 Hegi et al. assessed the MGMT 
promoter methylation status of patients randomized in the EORTC trial 26981/ NCIC CE.3 
trial.25 Regardless of treatment arm, OS was longer in patients with MGMT promoter 
methylation; 18.2 months compared with 12.2 months [HR for death 0·45 (95% CI 0·32 - 0·61)]. 
The magnitude of this effect was more substantial for patients receiving TMZ compared with 
those receiving radiation alone (P=0·007 vs. P=0·06, log-rank test). Of note, the majority of 
patients allocated to radiotherapy alone received alkylating agent chemotherapy as salvage 
treatment further supporting the use of concomitant therapy ‘upfront’ in newly diagnosed 
patients.25 The prognostic significance of MGMT promoter methylation status was prospectively 
corroborated in the RTOG 0525 randomized study of TMZ dose density in the adjuvant setting. 
In this study, dose-dense TMZ (n=422) failed to demonstrate a survival advantage over standard 
dosing (n=411).26 The absence of a TMZ-free control arm did not allow distinction between 
prognostic and predictive properties. 
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For elderly patients not suitable for the combined modality approach, recent evidence 
supports consideration of TMZ alone particularly for tumors harbouring MGMT promoter 
methylation.27 Temozolomide alone was assessed in the Nordic study,14 which found longer 
survival for both TMZ alone and hypofractionated radiotherapy over standard radiotherapy in 
patients older than 65 years of age. Comparison of TMZ and hypofractionated radiotherapy 
revealed no significant difference in overall survival (7·4 versus 8·4 months HR 0·82 95%CI 
0·63-1·06). In the head to head comparison of TMZ versus hypofractionated radiation, 36% of 
the TMZ recipients had subsequent radiation and 29% of the hypofractionated group had salvage 
chemotherapy. MGMT promoter methylation status was available in 258 (75%) of 342 patients. 
Patients with MGMT promoter methylated tumors receiving TMZ survived 2.9 months longer 
than those with unmethylated tumors (HR 0·56, 95% CI 0·34-0·93, p=0·02). No survival 
advantage was identified based on MGMT promoter methylation status within the cohort 
receiving radiation (HR 0·97, 95% CI 0·69-1·38, p=0·81). Although the intent for the TMZ 
group was to complete six cycles, at least two cycles were administered to 86% of patients, and 
only 34% completed all six cycles. Haematological toxicity as well as nausea and vomiting were 
more frequent as would be expected in the TMZ cohort. In addition, a treatment-related death 
involving thrombocytopenia highlights that prescribing chemotherapy is not without the potential 
for serious toxicity. 
 
In the NOA-08 study,13 192 patients received TMZ (1 week on, 1 week off schedule 100 
mg/m2 days 1–7) and 178 patients received 60Gy radiotherapy alone over 6–7 weeks to the 
gross tumour volume (GTV) + 2 centimeters. Median overall survival was similar for the two 
treatment arms: 8·6 months in the TMZ group and 9·6 months in the radiotherapy group (HR 
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1·09, 95% CI 0·84–1·42, p non-inferiority=0·033). MGMT promoter methylation status was 
available in 55% of patients receiving TMZ and 57% of patients receiving radiation with a 
predictive benefit seen for patients receiving the alkylating agent in the context of MGMT 
promoter methylated tumors. Hematological toxicity, abnormal liver function tests, infections 
and thromboembolic events were more prevalent in the TMZ group.  
 
These trials found that MGMT promoter methylation is a predictive biomarker of benefit 
from TMZ, but not radiotherapy. The randomized international NCIC/EORTC/TROG study, 
which completed accrual in September 2013 (JP, personal communication), aims to address the 
potential benefit of combining short course radiotherapy (40Gy in 15 fractions) with concurrent 
and adjuvant TMZ in patients over 65 years who have had prior surgery/biopsy at diagnosis and 
are not deemed suitable for the standard radiotherapy regimen of 60Gy.28 MGMT status will be 
assessed in this study. 
A phase 2 ANOCEF study suggests that older age and poor KPS should not preclude the 
use of TMZ alone.29 This was a non-randomized study which recruited 70 patients with a median 
age of 77 (range 70-87) and a median KPS of 60 (range 30-60). Intriguingly this study found an 
improvement of KPS in excess of 10 for 23 (33%) of treated patients with 18 (26%) having a rise 
to 70 or more. A maximum of 12 cycles of TMZ was planned however the median number of 
cycles received was only 2 with 20% and 24% of patients having dose delays and dose 
reductions for hematological toxicity respectively. Grade 3 or 4 hematological toxicities were not 
insignificant with 13% experiencing grade 3-4 neutropenia and 14% grade 3-4 
thrombocytopenia. No deaths were attributed to treatment. Although only 44% of patients were 
able to have tumor material assessed for MGMT promoter methylation, this study again 
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demonstrated its predictive role with a hazard ratio for death of 2.307(95% CI 1.073 to 4.962) for 
patients with unmethylated MGMT promoter status (P=0·03). This phase II study introduces the 
question – should more elderly patients with poor performance status be primarily treated with 
TMZ monotherapy? Or should TMZ monotherapy be employed only in those whose tumor 
harbors a methylated MGMT promoter?    
Although MGMT promoter methylation status is increasingly available it still not used in 
all centres. In the future increasing evidence favoring MGMT testing is likely to demand more 
widespread availability; for example the European Association for Neuro-Oncology (EANO) 
guideline for the diagnosis and treatment of malignant gliomas has already declared that MGMT 
promoter methylation status testing is standard of care30.  There have been some controversies 
regarding the methodology of MGMT testing, with some centers preferring pyrosequencing and 
others utilizing PCR. Immunohistochemistical assessment of MGMT does not appear to correlate 
with overall survival.31 
 
Bevacizumab 
Three uncontrolled studies indicate that the vascular endothelial growth factor (VEGF) 
antibody bevacizumab may have increased activity in elderly patients with glioblastoma.32-34 In 
2014, the efficacy of bevacizumab in newly diagnosed glioblastoma patients has been reported 
by two large, placebo-controlled, randomized trials.35,36 The Avastin in Glioblastoma (AVAglio) 
phase III study evaluated the effect of the addition of bevacizumab to focal radiotherapy with 
concurrent TMZ, to the adjuvant component and then beyond the adjuvant component until 
progression.34 Although improved progression-free survival (HR 0·65 (0·56–0·75)), preservation 
of baseline quality of life and performance status were reported, there was no improvement in 
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overall survival. Stratified by age over 70 years, the statistical significance with regards to PFS 
was lost [HR 0·78 (0·46–1·33)]; however this may reflect an issue of statistical power and small 
subgroups rather than a lack of clinical efficacy.  The RTOG 0825 trial, sharing a similar design, 
also failed to demonstrate an overall survival benefit35 but in contrast to the AVAglio study, a 
greater deterioration clinically assessed by patient reported outcome questionnaire, was evident 
in the bevacizumab group. There were differences in the design of these two studies that may 
influence determination of progression and patient reports outcomes.  Radiological assessment in 
the RTOG 0825 study was by serial measurement of cross-sectional diameter and use of the 
international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)37 
committee whereas the AVAglio study utilized an adaptation of the Macdonald criteria, similar 
to the newer RANO criteria, which takes into account the issues of pseudoprogression, 
pseudoresponse and changes in the non-enhancing disease.38  Ongoing discussion and analyses 
may further clarify the apparent discordant results with regard to progression-free survival  in 
these two pivotal trials.  
 No clinical or tissue based biomarkers have yet been prospectively shown to be 
associated with benefit from bevacizumab although patients with glioblastomas harbouring a 
proneural subtype may derive the most benefit.39 At present bevacizumab has no role in the 
standard upfront treatment of glioblastoma; however, future clinical trials may attempt to target 
specific groups of patients defined by sets of biomarkers. The randomized Avastin plus 
Radiotherapy in Elderly Patients with Glioblastoma (ARTE) study, a phase II trial, will explore 
whether the addition of bevacizumab to radiotherapy improves outcome in elderly patients with 
newly diagnosed glioblastoma without MGMT promoter methylation (M. Weller, personal 
communication). 
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Symptomatic management  
Glioblastoma can cause many difficult symptoms ranging from fatigue to those 
associated with raised intracranial pressure. Seizures may often occur as well as cognitive, motor 
or sensory deficits occurring in a location-dependent manner. Corticosteroids are often required 
to control symptoms of cerebral edema and their utility over time must be balanced with 
potential side effects such as proximal myopathy, steroid-induced diabetes, and osteoporotic 
fractures which can be debilitating. Furthermore, corticosteroids may reduce the benefit from 
TMZ in the most promising MGMT promoter methylated subgroup.40 Anti-seizure medications 
are also often warranted.  There is no randomised evidence pertaining to palliative care in the 
glioblastoma setting. However, based on a randomised study in non-small lung cancer, which 
demonstrated the addition of palliative care not only improved quality of life but also increased 
overall survival, many would advocate the early incorporation of palliative care support.41  
 
Population-based retrospective studies 
For glioblastoma, like many other cancers, results from randomized clinical trials (RCTs) 
may not reflect ‘real world” outcomes as described in population based studies. Several large 
population based studies have shown that many elderly patients do not receive the ‘gold 
standard’ treatment.  For example, despite the increasing body of evidence regarding the 
important benefit of resection rather than biopsy, numerous international pattern of care 
studies42-46 demonstrate a much higher rate of biopsy alone rather than attempted resection in the 
elderly population. 
The SEER database study published by Scott et. al. reported that among 2836 patients, 
only 46% of those over the age of 70 received both surgery and radiotherapy, with omission of 
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treatment associated with poorer survival.19 A similar SEER study of 4,137 patients with 
glioblastoma, aged 65 or older, reported a median overall survival of 4 months and described age 
to be associated with lower odds of resection and provision of RT or chemotherapy.19 The 
Princess Margaret Cancer Centre published outcomes of 131 patients aged greater than 70 
treated in the ‘temozolomide era’ between 2004 and 2008.47  Elderly patients were more likely to 
receive best supportive care or ‘palliative’ doses of radiotherapy with only 1 patient receiving 
60Gy in 30 fractions in combination with TMZ. Only 6 patients (5%) received TMZ post-
radiation, with only a median of 2.5 cycles administered.  A retrospective review of 235 patients 
aged 65 or over treated between 2006 and 2013 at the Odette Cancer Center in Toronto provides 
a more contemporary overview regarding provision of care in the elderly setting.48 With a 
median survival of approximately 2 months, 19% of patients were deemed not suitable for active 
treatment. 
There is a likely another subgroup of elderly patients not reflected in statistics who might 
be presumptively diagnosed on radiological investigations (e.g. imaging for suspected stroke) but 
for various reasons (e.g. comorbidities, patient and family preference) do not proceed even to a 
biopsy. Of course, in certain scenarios, e.g. bedbound patient with dementia, it may be 
inappropriate to pursue active management. 
Survivorship in the ‘real world’ would appear less favorable to that quoted in RCTs and 
may be a reflection of both physician preference to not to administer treatment in a group 
previously not studied as well as patient choice. The definition of ‘elderly’ varies across clinical 
trials and may appear to limit the ability to cross-compare data from these studies. That said, the 
NOA-08 trial had a median age of 72 (66-84) years in the TMZ arm and 72 (66-82) years in the 
RT arm. Age as a continuous variable or dichotomized at age 70 was not an independent 
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prognostic factor for either OS or event-free survival13; thus the association with age may not be 
as important in patients older than 70 years. Patients from population-based studies are clearly 
different that those included in the randomized trials. A patient-centered approach is important, 
as in all aspects of medicine, and treatment decisions need to involve a patient’s own preferences 
and goals of care should be a focus early in the discussion regarding management.   
 
Practical aspects: 
Practical considerations such as performance status and even the ability of the patient to 
get to appointments can also come into play, as many of these patients are no longer driving. For 
example, a mobile elderly patient with a poor short-term memory, but with a strong family 
network advocating for active treatment, is far more likely to be treated than a socially isolated 
patient. If a cognitively intact patient with poor mobility is keen for treatment; again the presence 
of supportive family will often make a difference impacting on decision-making. 
Often rehabilitation is not offered for glioblastoma patients postoperatively. However, 
there is evidence that postoperative rehabilitation in this setting is just as useful as in the stroke 
setting49,50 and should be considered where possible. There are observational studies which show 
improvement in patients’ functional status during the course of rehabilitation therapy, including 
the functional independence measure (FIM)51,52 and referral for rehabilitation is advocated.53 
Elderly patients and their caregivers may have numerous symptoms or challenges ahead. 
Challenges include treatment and tumor-related symptoms and deficits, seizures, headaches, 
communication difficulties (e.g. expressive or receptive aphasia), personality and behaviour 
changes (e.g. frontal syndrome with disinhibition and emotional lability), poor concentration, 
poor memory, fatigue, weakness, mobility; hemiparesis, impaired judgement/insight and 
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depression (reactive versus major). These challenges can be even more difficult to manage in the 
setting of comorbidities and polypharmacy often faced by elderly patients. 
The clinical journey is a complex one and can involve interaction with many health 
professionals- including neurosurgeon, radiation oncologist (and radiation therapists), medical 
oncologist, palliative care physician, occupational therapist, physiotherapist, neurologist, 
endocrinologist (for steroid-induced diabetes) or diabetic educator, social worker, pharmacist, 
psychologist, speech pathologist etc. and ideally a cancer care coordinator should be available, 
where possible, to help the patient navigate through this difficult pathway. 
Caregiver burnout is also very important for clinicians to be aware of. Recent studies 
have demonstrated that the global quality of life is often poorer in the caregiver than in the 
patients themselves.54,55 Often, in the elderly setting, a spouse (if there is one) has their own co-
morbidities to deal with and struggles to manage both physically and emotionally with the 
complexities involved with caring for a partner with glioblastoma.  
 
Conclusion and recommendations 
Selecting the appropriate treatment for an elderly patient with a newly diagnosed 
glioblastoma is challenging and a patient-centred approach is essential. Randomised evidence to 
guide treatment decisions is emerging (table 2) and there is less reason for nihilism. Initial 
consideration should include the appropriateness and extent of surgical intervention. With frailty 
and potential comorbidities there may be increased perioperative complications and prolonged 
recovery; however, maximal safe surgical resection should be considered. Subsequent 
management should incorporate initial symptomatic management including titration of 
corticosteroids and suitable anti-seizure medication if required.  Early introduction of palliative 
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care may have a role in many patients. Management should be based upon the fitness of the 
patient, performance status, and MGMT promoter methylation status (Figure 2).56 Standard 
radiotherapy of 60Gy in 30 fractions with concurrent and adjuvant TMZ can be utilized for most 
patients under the age of 70 and of appropriate fitness. In patients over the age of 70 there is 
evidence of efficacy for both radiotherapy alone and TMZ monotherapy respectively; the results 
of the NCIC-CTG/EORTC/TROG clinical trial will assess the benefit of hypofractionated 
radiotherapy with concurrent TMZ compared to radiotherapy alone. Most patients over 70 years 
of age appear not to benefit from conventional radiation schedules such as 60Gy in 30 fractions 
and a hypofractionated schedule is recommended. We acknowledge that some practitioners 
continue to recommend radical treatment (60Gy in 30 fractions with TMZ) for fit patients over 
the age of 70; however there are no randomized data to support this practice. MGMT may turn 
out to be even more important in the setting of elderly patients than in younger patients in terms 
of guiding management decisions. Ideally MGMT promoter methylation status should be 
determined on all patients 65 years and older. Patients lacking MGMT promoter methylation 
should be considered for a course of hypofractionated radiation therapy alone while those with 
methylated tumors may be offered temozolomide alone. Selection of these treatments requires an 
interdisciplinary discussion of the risks and benefits of RT versus TMZ, incorporation of the 
patient’s own goals of care, and patient preference.  
Some of the current algorithms for elderly glioblastoma patients are based on 
extrapolations from small and underpowered studies, but hopefully over the next few years, 
higher levels of evidence from larger maturing phase III studies will ensure future 
recommendations are more robust. 
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Figure Legends 
Figure 1:  Overall Survival of Glioblastoma Patients Treated in Ontario, Canada Stratified by 
Decade of Age 
Figure 2 Figure 2: Flow diagram of treatment considerations for elderly Glioblastoma patients (a) 
65-70 and (b) >70 
Table Legends 
Table 1:  Average age adjusted incidence per 100,000 and relative survival for GB stratified by age 
(CBTRUS)2 
  Table 2:  Randomised clinical evidence for elderly glioblastoma patients. 
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Abstract: 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The median age 
of diagnosis is 64 years, with an increasing number of patients diagnosed over the age of 
seventy. Managing elderly patients with this condition is challenging. Management pathways 
may include surgery, radiotherapy (RT), chemotherapy and best supportive care (BSC). Many 
clinical trials in oncology exclude elderly patients, including some of those for malignant brain 
tumors leaving less evidence to guide treatment in the these patients. Recent advances in 
molecular diagnostics and biomarkers, such as 06-methylguanine-DNA-methyltransferase 
(MGMT) promoter methylation status, may help guide optimal treatment selection. Focusing on 
available randomized data, this review provides a practical overview of the evidence for the 
treatment of newly diagnosed glioblastoma in the elderly including management 
recommendations.  
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4 
 
 
 
 
Convention is to define the ‘elderly’ population as exceeding a specified chronological 
age which varies with temporal, geographical, social and cultural factors. Managing elderly 
patients can be challenging; medical comorbidities, multiple concomitant medications, and 
increasing fragility of health alter drug efficacy and the magnitude and spectrum of adverse 
effects related to treatment. With age, the natural insidious change of physiology and constitution 
affects pharmacokinetic processes with regards to absorption, metabolism, distribution and drug 
clearance.1 Many clinical trials in oncology exclude elderly patients, including some of those for 
malignant brain tumors; as such there is less evidence to guide treatment in the elderly cohort.  
This review provides a practical overview of the evidence for the treatment of newly diagnosed 
glioblastoma in the elderly.  
 
 
Epidemiology 
 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The 
Central Brain Tumour Registry of the United States (CBTRUS) statistical report, which collates 
epidemiological data from over 50 state cancer registries, identified 112,458 malignant primary 
brain and central nervous system (CNS) tumors between 2006 and 2010 of which 45.2% were 
glioblastomas.2 A median age of 64 at diagnosis and an average age-adjusted incidence rate per 
of 3·19 (3·16-3·21) per 100,000 were reported. Stratification by age detected an increase in 
incidence with age, and the peak rate of 14·93 in the 75-84 age range. Of note is the marked 
decrease in survival with advancing age (table 1). The 1-year and 2-year relative survival rates of 
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40·7% and 14·2% for patients aged 55-64 falls to 9·2% and 2·6% for patients aged 75 or older.  
An Ontario (Canada) population-based cohort study of all patients diagnosed with glioblastoma 
between 1982 and 1994 found poorer survival with respect to each increasing decade of age 
(Figure 1 courtesy of Paszat et. al. Unpublished 1999). Whether this poorer survival is a 
reflection of differing provisions of care based on chronological age or reflects more aggressive 
tumor biology, or both, is presently unclear.   
 
The histologic hallmarks of glioblastoma, as defined by the World Health Organization 
(WHO), include cellular polymorphism, nuclear atypia, a high mitotic index, microvascular 
proliferation and necrosis.3 With the emergence of personalized medicine, molecular diagnostics 
are increasingly used to improve the treatment and survival associated with glioblastoma.  
Prognostic biomarkers such as TP53 mutation, 1p deletion, cyclin dependent kinase (CDK) 
N2A/p16 deletion and epidermal growth factor receptor (EGFR) amplification vary with age4. In 
a histological review of 140 patients, TP53 mutations and EGFR amplification had differing 
prognostic significance when stratifying by age, with TP53 mutations being positively prognostic 
for younger patients and negative for older patients (<70yrs 0.84; 95% CI 0.49 –1.42 versus 
>70yrs HR 7.54; 95% CI 2.38–23.87)4. Conversely EGFR amplification in the context of older 
patients was positively prognostic yet in younger patients it was negatively prognostic.4  
 
More recently gene expression-based molecular analysis has been utilized to categorize 
glioblastoma into subtypes including proneural, neural, classical and mesenchymal subtypes.5 
Lee et al. performed a meta-analysis which substantiated the presence of these subtypes, as 
identified by genetic signature and suggested that the prognostic effect of age may in fact be a 
reflection of the differing prevalence of specific subtypes at differing ages; for example the 
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proneural subtype appears to occur more often in younger patients and is associated with longer 
survival.6 Presently these markers do not have a defined role in clinical practice with regards to 
daily management decisions and remain under investigation.  Of note, positive prognostic 
biomarkers, like mutations of isocitrate dehydrogenase (IDH) are virtually absent in 
glioblastoma of the elderly; similarly the general DNA methylation levels in the tumor tissue 
seem to be low. Despite this the frequency of O6-Methylguanine-DNA methyltransferase 
(MGMT) promoter methylation, itself an important positive predictive marker, does not vary 
with age.7 
 
Surgery  
In younger patients, maximal safe resection is advocated with the intent of preserving 
neurological function, providing maximal tissue for molecular profiling, and improving overall 
survival. Analysis of the extent of surgery in Radiation Therapy Oncology Group (RTOG) 
randomised trials, found significant improvement in survival with partial/total resection versus 
biopsy alone.8 Review of an unselected population of 345 newly diagnosed glioblastoma patients 
from the German Glioma Network (GGN) demonstrated gross tumour resection to be associated 
with superior overall survival (OS) (median 17·1 months) compared to incomplete resection 
(median 11·7 months) and biopsy alone (median 8·7 months).9 A multivariate analysis of 416 
glioblastoma patients treated at a single institution between 1993 and 1999 reported resections of 
tumour volume in the order of 98% or greater to be associated with significant survival 
advantage (median survival 13 months, 95% CI 11·4–14·6 months versus 8·8 months (95% CI 
7·4–10·2 months; p < 0·0001).10  
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There is one randomized trial pertaining to surgical intervention, including elderly 
patients with glioblastoma. This small study of 30 patients assessed the role of debulking surgery 
compared to biopsy alone.11  Patients aged 65 or older with KPS >60 were randomized to open 
craniotomy and resection [14 patients with a median age of 70 (66-80)] or stereotactic biopsy [16 
patients with a median of age 72 (67 -79)]. Surgical resection resulted in superior overall survival 
(171 days (95% CI 146–278) vs. 85 days (95% CI 55–157) p = 0·0346). More recently, a case-
control study with a subgroup analysis of 52 patients aged 70 or over found a median survival of 
4·5 months and 3 months for surgical resection and needle biopsy respectively (p = 0·03).12 
Perhaps the most relevant trial for the topic is the Neuro-oncology Working Group of the 
German Cancer Society NOA-08 study which found extent of surgery to be an independent 
prognostic factor for overall survival among glioblastoma patients 65 years and older.13 
Furthermore, multivariate analysis of all patients (n=342) participating in the Nordic trial of 
standard vs. hypofractionated radiotherapy vs. chemotherapy alone in newly diagnosed 
glioblastoma patients 65 years of age or older also demonstrated a survival benefit favoring 
surgery over biopsy alone (biopsy versus resection HR 1·50 (1·17 -1·92) p =0·001).14 
 
Standard post-operative management for newly diagnosed glioblastoma 
The European Organisation for Research and Treatment of Cancer (EORTC) 26981-
22981/National Cancer Institute of Canada Clinical Trials Group (NCIC) CE.3 randomised phase 
III trial assessed the addition of temozolomide (TMZ) to radiotherapy (RT) in the concomitant 
and sequential adjuvant setting in glioblastoma patients aged 18-70.15  Median age was 56 (range 
19-71) and the selected population required Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–2. The addition of TMZ resulted in a median survival benefit of 2·5 
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months; 14·6 months (95% CI 13·2- 16·8) compared with 12·1 months (95%CI 11·2 -13·0) for 
radiotherapy alone. The 5-year analysis of this trial confirmed a persisting advantage and this has 
become the standard of care post-surgical resection for patients less than 70 years of age and of 
appropriate performance status.16 In a recent review Laperriere et. al. noted that subgroup 
analysis of this trial demonstrated a trend to benefit in the more elderly subgroups, albeit with a 
less impressive hazard ratio and without reaching statistical significance. Specifically, there was 
diminishing benefit of combined treatment with increasing age (61-65 years: HR 0.64 p = 0.096 
and 66–70 years: HR = 0·78 p = 0·34) compared to the overall group (HR 0·6, 95%CI 0·5-0·7; 
p<0·0001).17 This may reflect less robust effects of the combined approach in the elderly or may 
be due to lower statistical power in the subgroup analysis. 
 
Radiation for elderly patients 
Randomized trials have long demonstrated a survival benefit from post-operative 
radiotherapy in the management of glioblastoma and more recently several trials have focused on 
the elderly. The French ANOCEF group found a median survival benefit of 12.2 weeks in favour 
of RT plus best supportive care (BSC) versus BSC alone.18 Patients aged 70 or older with a KPS 
>70 and a diagnosis of glioblastoma or anaplastic astrocytoma were randomized postoperatively 
to receive BSC [(42 patients (median age 73; range 70-85)] or BSC and 50 Gy in 1.8 Gy 
fractions to a clinical target volume (CTV) consisting of enhancing tumour with a 2cm margin 
[(39 patients (median age 75; range 70-84)]. Overall survival was 16·9 (95% CI, 13·4 to 21·4) 
and 29·1 weeks (95% CI, 25·4 to 34·9) respectively. No significant difference was detected with 
regards to quality of life; however, Health Related Quality of Life (HRQoL) assessments were 
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incomplete.  Cox proportional hazard modelling revealed that extent of surgery was associated 
with increased survival.  
Scott et al. performed a large retrospective review of elderly glioblastoma patients 
diagnosed between 1993 and 2005.19 The study sample of 2836 patients identified from the 
Surveillance, Epidemiology, and End Results (SEER) registry database had a median age of 76·9 
years (range 71·0–98·0). Kaplan-Meier analysis revealed median cancer-specific survivals of 8 
months for patients undergoing both surgery and postoperative radiotherapy, 4 months for 
radiation alone, 3 months for surgery alone and 2 months for neither surgery nor radiotherapy 
(log rank p<0·001). Multivariate analysis suggested radiotherapy significantly increased cancer-
specific survival after adjusting for tumour size, tumour location, surgery and patient 
demographics with a hazard ratio (HR) of 0·43 (95% CI, 0·38–0·49). 19 
The biological effect of radiation on tumour and normal tissues is dependent upon the 
provision of dose over time as well as intrinsic radio-sensitivity (α) and repair capability (ß). 
Glioblastoma has an alpha-beta ratio (α/ ß) = 8Gy (5·0–10·8)20 which is in the range of most 
tumours, while the alpha-beta ratio is approximately 2 for the normal central nervous system. As 
a result of this difference, hypofractionation reduces overall treatment time and may minimize 
the potential for tumor cell repopulation and provides a practical convenience for an elderly frail 
population. Roa et. al. randomized patients aged 60 or older to radiotherapy given as 60Gy in 30 
fractions (47 patients, mean age 72.4 yrs, SD 5·4) or a hypofractionated regimen of 40Gy in 15 
fractions (48 patients, mean 71·0 yrs, SD 5·5).21 While this study was not sufficiently powered to 
conclude equivalence of these two fractionation schedules it suggested no significant differences 
in OS [median 5.1 months for the standard RT arm versus 5·6 months for the shorter course (log 
rank p = 0·57)], survival at 6 months (44·7% standard RT versus 41·7% hypofractionated RT), 
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or HRQoL.  More patients required an increase of corticosteroid dose following the standard 
radiotherapy schedule compared to the hypofractionated course (p= 0·02). 
The Nordic trial incorporated a different hypofractionated radiotherapy schedule.14 There 
were 3 treatment arms including standard radiotherapy of 60Gy in 30 fractions, hypofractionated 
radiotherapy of 34Gy in 10 fractions or temozolomide 200mg/m2 days 1-5 every 28 days for up 
to 6 cycles. Standard radiotherapy (60Gy/30) was not routinely offered to elderly patients in 
some study sites so randomization between just the hypofractionated radiotherapy and 
temozolomide arms was permitted.  Two hundred and ninety one glioblastoma patients (initially 
aged 60 years or older then in view of EORTC 26981-22981/NCIC-CTG CE.3 the age eligibility 
was adjusted so that patients 60-65 years old fit for combined treatment were excluded) were 
randomized to standard radiotherapy (n=100), hypofractionated radiotherapy (n=98) or 
temozolomide alone (n=93). A further 51 patients were randomized to either hypofractionated 
radiotherapy (n=25) or TMZ (n=26) by those centers that did not offer 60Gy in 30 fractions as 
their standard care. 
The median age was 70 for both the hypofractionated and the standard radiotherapy 
groups. Median survival in the hypofractionated group was increased by 1·5 months compared to 
standard radiation in the three-arm comparison. Interestingly, on stratification by age, the 
advantage of hypofractionated radiation appeared better in patients over the age of 70 (7·0 (5·2–
8·8) versus 5·2 (4·0–6·3) months). Treatment completion according to protocol was more 
frequent with the hypofractionated schedule (95% versus 72%). Salvage treatment was received 
for a similar proportion of patients in both groups while reported toxicity was not different 
between groups.   
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Temozolomide and O-6-methylguanine-DNA methyltransferase  
The alkylating agent TMZ has activity in glioblastoma, and in combination with 
radiotherapy followed sequentially by a 6 month maintenance course represents the current 
standard of care for many patients. The mechanism of anti-tumour activity is believed to arise 
through methylation of DNA at the O-6 position of guanine by monomethyl-triazeno-imidazole-
carboxyamide (MTIC), a non-enzymatic chemical degradation product of temozolomide.22     
MGMT is a DNA repair protein implicated in resistance to alkylating agents.23  
Methylation of the MGMT promoter, located at 10q26, leads to suppression of MGMT gene 
expression and an increased likelihood of clinical benefit.23-25 Hegi et al. assessed the MGMT 
promoter methylation status of patients randomized in the EORTC trial 26981/ NCIC CE.3 
trial.25 Regardless of treatment arm, OS was longer in patients with MGMT promoter 
methylation; 18.2 months compared with 12.2 months [HR for death 0·45 (95% CI 0·32 - 0·61)]. 
The magnitude of this effect was more substantial for patients receiving TMZ compared with 
those receiving radiation alone (P=0·007 vs. P=0·06, log-rank test). Of note, the majority of 
patients allocated to radiotherapy alone received alkylating agent chemotherapy as salvage 
treatment further supporting the use of concomitant therapy ‘upfront’ in newly diagnosed 
patients.25 The prognostic significance of MGMT promoter methylation status was prospectively 
corroborated in the RTOG 0525 randomized study of TMZ dose density in the adjuvant setting. 
In this study, dose-dense TMZ (n=422) failed to demonstrate a survival advantage over standard 
dosing (n=411).26 The absence of a TMZ-free control arm did not allow distinction between 
prognostic and predictive properties. 
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For elderly patients not suitable for the combined modality approach, recent evidence 
supports consideration of TMZ alone particularly for tumors harbouring MGMT promoter 
methylation.27 Temozolomide alone was assessed in the Nordic study,14 which found longer 
survival for both TMZ alone and hypofractionated radiotherapy over standard radiotherapy in 
patients older than 65 years of age. Comparison of TMZ and hypofractionated radiotherapy 
revealed no significant difference in overall survival (7·4 versus 8·4 months HR 0·82 95%CI 
0·63-1·06). In the head to head comparison of TMZ versus hypofractionated radiation, 36% of 
the TMZ recipients had subsequent radiation and 29% of the hypofractionated group had salvage 
chemotherapy. MGMT promoter methylation status was available in 258 (75%) of 342 patients. 
Patients with MGMT promoter methylated tumors receiving TMZ survived 2.9 months longer 
than those with unmethylated tumors (HR 0·56, 95% CI 0·34-0·93, p=0·02). No survival 
advantage was identified based on MGMT promoter methylation status within the cohort 
receiving radiation (HR 0·97, 95% CI 0·69-1·38, p=0·81). Although the intent for the TMZ 
group was to complete six cycles, at least two cycles were administered to 86% of patients, and 
only 34% completed all six cycles. Haematological toxicity as well as nausea and vomiting were 
more frequent as would be expected in the TMZ cohort. In addition, a treatment-related death 
involving thrombocytopenia highlights that prescribing chemotherapy is not without the potential 
for serious toxicity. 
 
In the NOA-08 study,13 192 patients received TMZ (1 week on, 1 week off schedule 100 
mg/m2 days 1–7) and 178 patients received 60Gy radiotherapy alone over 6–7 weeks to the 
gross tumour volume (GTV) + 2 centimeters. Median overall survival was similar for the two 
treatment arms: 8·6 months in the TMZ group and 9·6 months in the radiotherapy group (HR 
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1·09, 95% CI 0·84–1·42, p non-inferiority=0·033). MGMT promoter methylation status was 
available in 55% of patients receiving TMZ and 57% of patients receiving radiation with a 
predictive benefit seen for patients receiving the alkylating agent in the context of MGMT 
promoter methylated tumors. Hematological toxicity, abnormal liver function tests, infections 
and thromboembolic events were more prevalent in the TMZ group.  
 
These trials found that MGMT promoter methylation is a predictive biomarker of benefit 
from TMZ, but not radiotherapy. The randomized international NCIC/EORTC/TROG study, 
which completed accrual in September 2013 (JP, personal communication), aims to address the 
potential benefit of combining short course radiotherapy (40Gy in 15 fractions) with concurrent 
and adjuvant TMZ in patients over 65 years who have had prior surgery/biopsy at diagnosis and 
are not deemed suitable for the standard radiotherapy regimen of 60Gy.28 MGMT status will be 
assessed in this study. 
A phase 2 ANOCEF study suggests that older age and poor KPS should not preclude the 
use of TMZ alone.29 This was a non-randomized study which recruited 70 patients with a median 
age of 77 (range 70-87) and a median KPS of 60 (range 30-60). Intriguingly this study found an 
improvement of KPS in excess of 10 for 23 (33%) of treated patients with 18 (26%) having a rise 
to 70 or more. A maximum of 12 cycles of TMZ was planned however the median number of 
cycles received was only 2 with 20% and 24% of patients having dose delays and dose 
reductions for hematological toxicity respectively. Grade 3 or 4 hematological toxicities were not 
insignificant with 13% experiencing grade 3-4 neutropenia and 14% grade 3-4 
thrombocytopenia. No deaths were attributed to treatment. Although only 44% of patients were 
able to have tumor material assessed for MGMT promoter methylation, this study again 
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demonstrated its predictive role with a hazard ratio for death of 2.307(95% CI 1.073 to 4.962) for 
patients with unmethylated MGMT promoter status (P=0·03). This phase II study introduces the 
question – should more elderly patients with poor performance status be primarily treated with 
TMZ monotherapy? Or should TMZ monotherapy be employed only in those whose tumor 
harbors a methylated MGMT promoter?    
Although MGMT promoter methylation status is increasingly available it still not used in 
all centres. In the future increasing evidence favoring MGMT testing is likely to demand more 
widespread availability; for example the European Association for Neuro-Oncology (EANO) 
guideline for the diagnosis and treatment of malignant gliomas has already declared that MGMT 
promoter methylation status testing is standard of care30.  There have been some controversies 
regarding the methodology of MGMT testing, with some centers preferring pyrosequencing and 
others utilizing PCR. Immunohistochemistical assessment of MGMT does not appear to correlate 
with overall survival.31 
 
Bevacizumab 
Three uncontrolled studies indicate that the vascular endothelial growth factor (VEGF) 
antibody bevacizumab may have increased activity in elderly patients with glioblastoma.32-34 In 
2014, the efficacy of bevacizumab in newly diagnosed glioblastoma patients has been reported 
by two large, placebo-controlled, randomized trials.35,36 The Avastin in Glioblastoma (AVAglio) 
phase III study evaluated the effect of the addition of bevacizumab to focal radiotherapy with 
concurrent TMZ, to the adjuvant component and then beyond the adjuvant component until 
progression.34 Although improved progression-free survival (HR 0·65 (0·56–0·75)), preservation 
of baseline quality of life and performance status were reported, there was no improvement in 
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overall survival. Stratified by age over 70 years, the statistical significance with regards to PFS 
was lost [HR 0·78 (0·46–1·33)]; however this may reflect an issue of statistical power and small 
subgroups rather than a lack of clinical efficacy.  The RTOG 0825 trial, sharing a similar design, 
also failed to demonstrate an overall survival benefit35 but in contrast to the AVAglio study, a 
greater deterioration clinically assessed by patient reported outcome questionnaire, was evident 
in the bevacizumab group. There were differences in the design of these two studies that may 
influence determination of progression and patient reports outcomes.  Radiological assessment in 
the RTOG 0825 study was by serial measurement of cross-sectional diameter and use of the 
international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)37 
committee whereas the AVAglio study utilized an adaptation of the Macdonald criteria, similar 
to the newer RANO criteria, which takes into account the issues of pseudoprogression, 
pseudoresponse and changes in the non-enhancing disease.38  Ongoing discussion and analyses 
may further clarify the apparent discordant results with regard to progression-free survival  in 
these two pivotal trials.  
 No clinical or tissue based biomarkers have yet been prospectively shown to be 
associated with benefit from bevacizumab although patients with glioblastomas harbouring a 
proneural subtype may derive the most benefit.39 At present bevacizumab has no role in the 
standard upfront treatment of glioblastoma; however, future clinical trials may attempt to target 
specific groups of patients defined by sets of biomarkers. The randomized Avastin plus 
Radiotherapy in Elderly Patients with Glioblastoma (ARTE) study, a phase II trial, will explore 
whether the addition of bevacizumab to radiotherapy improves outcome in elderly patients with 
newly diagnosed glioblastoma without MGMT promoter methylation (M. Weller, personal 
communication). 
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Symptomatic management  
Glioblastoma can cause many difficult symptoms ranging from fatigue to those 
associated with raised intracranial pressure. Seizures may often occur as well as cognitive, motor 
or sensory deficits occurring in a location-dependent manner. Corticosteroids are often required 
to control symptoms of cerebral edema and their utility over time must be balanced with 
potential side effects such as proximal myopathy, steroid-induced diabetes, and osteoporotic 
fractures which can be debilitating. Furthermore, corticosteroids may reduce the benefit from 
TMZ in the most promising MGMT promoter methylated subgroup.40 Anti-seizure medications 
are also often warranted.  There is no randomised evidence pertaining to palliative care in the 
glioblastoma setting. However, based on a randomised study in non-small lung cancer, which 
demonstrated the addition of palliative care not only improved quality of life but also increased 
overall survival, many would advocate the early incorporation of palliative care support.41  
 
Population-based retrospective studies 
For glioblastoma, like many other cancers, results from randomized clinical trials (RCTs) 
may not reflect ‘real world” outcomes as described in population based studies. Several large 
population based studies have shown that many elderly patients do not receive the ‘gold 
standard’ treatment.  For example, despite the increasing body of evidence regarding the 
important benefit of resection rather than biopsy, numerous international pattern of care 
studies42-46 demonstrate a much higher rate of biopsy alone rather than attempted resection in the 
elderly population. 
The SEER database study published by Scott et. al. reported that among 2836 patients, 
only 46% of those over the age of 70 received both surgery and radiotherapy, with omission of 
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treatment associated with poorer survival.19 A similar SEER study of 4,137 patients with 
glioblastoma, aged 65 or older, reported a median overall survival of 4 months and described age 
to be associated with lower odds of resection and provision of RT or chemotherapy.19 The 
Princess Margaret Cancer Centre published outcomes of 131 patients aged greater than 70 
treated in the ‘temozolomide era’ between 2004 and 2008.47  Elderly patients were more likely to 
receive best supportive care or ‘palliative’ doses of radiotherapy with only 1 patient receiving 
60Gy in 30 fractions in combination with TMZ. Only 6 patients (5%) received TMZ post-
radiation, with only a median of 2.5 cycles administered.  A retrospective review of 235 patients 
aged 65 or over treated between 2006 and 2013 at the Odette Cancer Center in Toronto provides 
a more contemporary overview regarding provision of care in the elderly setting.48 With a 
median survival of approximately 2 months, 19% of patients were deemed not suitable for active 
treatment. 
There is a likely another subgroup of elderly patients not reflected in statistics who might 
be presumptively diagnosed on radiological investigations (e.g. imaging for suspected stroke) but 
for various reasons (e.g. comorbidities, patient and family preference) do not proceed even to a 
biopsy. Of course, in certain scenarios, e.g. bedbound patient with dementia, it may be 
inappropriate to pursue active management. 
Survivorship in the ‘real world’ would appear less favorable to that quoted in RCTs and 
may be a reflection of both physician preference to not to administer treatment in a group 
previously not studied as well as patient choice. The definition of ‘elderly’ varies across clinical 
trials and may appear to limit the ability to cross-compare data from these studies. That said, the 
NOA-08 trial had a median age of 72 (66-84) years in the TMZ arm and 72 (66-82) years in the 
RT arm. Age as a continuous variable or dichotomized at age 70 was not an independent 
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prognostic factor for either OS or event-free survival13; thus the association with age may not be 
as important in patients older than 70 years. Patients from population-based studies are clearly 
different that those included in the randomized trials. A patient-centered approach is important, 
as in all aspects of medicine, and treatment decisions need to involve a patient’s own preferences 
and goals of care should be a focus early in the discussion regarding management.   
 
Practical aspects: 
Practical considerations such as performance status and even the ability of the patient to 
get to appointments can also come into play, as many of these patients are no longer driving. For 
example, a mobile elderly patient with a poor short-term memory, but with a strong family 
network advocating for active treatment, is far more likely to be treated than a socially isolated 
patient. If a cognitively intact patient with poor mobility is keen for treatment; again the presence 
of supportive family will often make a difference impacting on decision-making. 
Often rehabilitation is not offered for glioblastoma patients postoperatively. However, 
there is evidence that postoperative rehabilitation in this setting is just as useful as in the stroke 
setting49,50 and should be considered where possible. There are observational studies which show 
improvement in patients’ functional status during the course of rehabilitation therapy, including 
the functional independence measure (FIM)51,52 and referral for rehabilitation is advocated.53 
Elderly patients and their caregivers may have numerous symptoms or challenges ahead. 
Challenges include treatment and tumor-related symptoms and deficits, seizures, headaches, 
communication difficulties (e.g. expressive or receptive aphasia), personality and behaviour 
changes (e.g. frontal syndrome with disinhibition and emotional lability), poor concentration, 
poor memory, fatigue, weakness, mobility; hemiparesis, impaired judgement/insight and 
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depression (reactive versus major). These challenges can be even more difficult to manage in the 
setting of comorbidities and polypharmacy often faced by elderly patients. 
The clinical journey is a complex one and can involve interaction with many health 
professionals- including neurosurgeon, radiation oncologist (and radiation therapists), medical 
oncologist, palliative care physician, occupational therapist, physiotherapist, neurologist, 
endocrinologist (for steroid-induced diabetes) or diabetic educator, social worker, pharmacist, 
psychologist, speech pathologist etc. and ideally a cancer care coordinator should be available, 
where possible, to help the patient navigate through this difficult pathway. 
Caregiver burnout is also very important for clinicians to be aware of. Recent studies 
have demonstrated that the global quality of life is often poorer in the caregiver than in the 
patients themselves.54,55 Often, in the elderly setting, a spouse (if there is one) has their own co-
morbidities to deal with and struggles to manage both physically and emotionally with the 
complexities involved with caring for a partner with glioblastoma.  
 
Conclusion and recommendations 
Selecting the appropriate treatment for an elderly patient with a newly diagnosed 
glioblastoma is challenging and a patient-centred approach is essential. Randomised evidence to 
guide treatment decisions is emerging (table 2) and there is less reason for nihilism. Initial 
consideration should include the appropriateness and extent of surgical intervention. With frailty 
and potential comorbidities there may be increased perioperative complications and prolonged 
recovery; however, maximal safe surgical resection should be considered. Subsequent 
management should incorporate initial symptomatic management including titration of 
corticosteroids and suitable anti-seizure medication if required.  Early introduction of palliative 
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care may have a role in many patients. Management should be based upon the fitness of the 
patient, performance status, and MGMT promoter methylation status (Figure 2).56 Standard 
radiotherapy of 60Gy in 30 fractions with concurrent and adjuvant TMZ can be utilized for most 
patients under the age of 70 and of appropriate fitness. In patients over the age of 70 there is 
evidence of efficacy for both radiotherapy alone and TMZ monotherapy respectively; the results 
of the NCIC-CTG/EORTC/TROG clinical trial will assess the benefit of hypofractionated 
radiotherapy with concurrent TMZ compared to radiotherapy alone. Most patients over 70 years 
of age appear not to benefit from conventional radiation schedules such as 60Gy in 30 fractions 
and a hypofractionated schedule is recommended. MGMT may turn out to be even more 
important in the setting of elderly patients than in younger patients in terms of guiding 
management decisions. Ideally MGMT promoter methylation status should be determined on all 
patients 65 years and older. Patients lacking MGMT promoter methylation should be considered 
for a course of hypofractionated radiation therapy alone while those with methylated tumors may 
be offered temozolomide alone. Selection of these treatments requires an interdisciplinary 
discussion of the risks and benefits of RT versus TMZ, incorporation of the patient’s own goals 
of care, and patient preference.  
Some of the current algorithms for elderly glioblastoma patients are based on 
extrapolations from small and underpowered studies, but hopefully over the next few years, 
higher levels of evidence from larger maturing phase III studies will ensure future 
recommendations are more robust. 
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Abstract: 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The median age 
of diagnosis is 64 years, with an increasing number of patients diagnosed over the age of 
seventy. Managing elderly patients with this condition is challenging. Management pathways 
may include surgery, radiotherapy (RT), chemotherapy and best supportive care (BSC). Many 
clinical trials in oncology exclude elderly patients, including some of those for malignant brain 
tumors leaving less evidence to guide treatment in the these patients. Recent advances in 
molecular diagnostics and biomarkers, such as 06-methylguanine-DNA-methyltransferase 
(MGMT) promoter methylation status, may help guide optimal treatment selection. Focusing on 
available randomized data, this review provides a practical overview of the evidence for the 
treatment of newly diagnosed glioblastoma in the elderly including management 
recommendations.  
 
Keywords: Elderly, glioblastoma, surgery, radiotherapy, chemotherapy 
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Convention is to define the ‘elderly’ population as exceeding a specified chronological 
age which varies with temporal, geographical, social and cultural factors. Managing elderly 
patients can be challenging; medical comorbidities, multiple concomitant medications, and 
increasing fragility of health alter drug efficacy and the magnitude and spectrum of adverse 
effects related to treatment. With age, the natural insidious change of physiology and constitution 
affects pharmacokinetic processes with regards to absorption, metabolism, distribution and drug 
clearance.1 Many clinical trials in oncology exclude elderly patients, including some of those for 
malignant brain tumors; as such there is less evidence to guide treatment in the elderly cohort.  
This review provides a practical overview of the evidence for the treatment of newly diagnosed 
glioblastoma in the elderly.  
 
 
Epidemiology 
 
Glioblastoma is a highly malignant neoplasm, notorious for its poor prognosis. The 
Central Brain Tumour Registry of the United States (CBTRUS) statistical report, which collates 
epidemiological data from over 50 state cancer registries, identified 112,458 malignant primary 
brain and central nervous system (CNS) tumors between 2006 and 2010 of which 45.2% were 
glioblastomas.2 A median age of 64 at diagnosis and an average age-adjusted incidence rate per 
of 3·19 (3·16-3·21) per 100,000 were reported. Stratification by age detected an increase in 
incidence with age, and the peak rate of 14·93 in the 75-84 age range. Of note is the marked 
decrease in survival with advancing age (table 1). The 1-year and 2-year relative survival rates of 
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40·7% and 14·2% for patients aged 55-64 falls to 9·2% and 2·6% for patients aged 75 or older.  
An Ontario (Canada) population-based cohort study of all patients diagnosed with glioblastoma 
between 1982 and 1994 found poorer survival with respect to each increasing decade of age 
(Figure 1 courtesy of Paszat et. al. Unpublished 1999). Whether this poorer survival is a 
reflection of differing provisions of care based on chronological age or reflects more aggressive 
tumor biology, or both, is presently unclear.   
 
The histologic hallmarks of glioblastoma, as defined by the World Health Organization 
(WHO), include cellular polymorphism, nuclear atypia, a high mitotic index, microvascular 
proliferation and necrosis.3 With the emergence of personalized medicine, molecular diagnostics 
are increasingly used to improve the treatment and survival associated with glioblastoma.  
Prognostic biomarkers such as TP53 mutation, 1p deletion, cyclin dependent kinase (CDK) 
N2A/p16 deletion and epidermal growth factor receptor (EGFR) amplification vary with age4. In 
a histological review of 140 patients, TP53 mutations and EGFR amplification had differing 
prognostic significance when stratifying by age, with TP53 mutations being positively prognostic 
for younger patients and negative for older patients (<70yrs 0.84; 95% CI 0.49 –1.42 versus 
>70yrs HR 7.54; 95% CI 2.38–23.87)4. Conversely EGFR amplification in the context of older 
patients was positively prognostic yet in younger patients it was negatively prognostic.4  
 
More recently gene expression-based molecular analysis has been utilized to categorize 
glioblastoma into subtypes including proneural, neural, classical and mesenchymal subtypes.5 
Lee et al. performed a meta-analysis which substantiated the presence of these subtypes, as 
identified by genetic signature and suggested that the prognostic effect of age may in fact be a 
reflection of the differing prevalence of specific subtypes at differing ages; for example the 
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proneural subtype appears to occur more often in younger patients and is associated with longer 
survival.6 Presently these markers do not have a defined role in clinical practice with regards to 
daily management decisions and remain under investigation.  Of note, positive prognostic 
biomarkers, like mutations of isocitrate dehydrogenase (IDH) are virtually absent in 
glioblastoma of the elderly; similarly the general DNA methylation levels in the tumor tissue 
seem to be low. Despite this the frequency of O6-Methylguanine-DNA methyltransferase 
(MGMT) promoter methylation, itself an important positive predictive marker, does not vary 
with age.7 
 
Surgery  
In younger patients, maximal safe resection is advocated with the intent of preserving 
neurological function, providing maximal tissue for molecular profiling, and improving overall 
survival. Analysis of the extent of surgery in Radiation Therapy Oncology Group (RTOG) 
randomised trials, found significant improvement in survival with partial/total resection versus 
biopsy alone.8 Review of an unselected population of 345 newly diagnosed glioblastoma patients 
from the German Glioma Network (GGN) demonstrated gross tumour resection to be associated 
with superior overall survival (OS) (median 17·1 months) compared to incomplete resection 
(median 11·7 months) and biopsy alone (median 8·7 months).9 A multivariate analysis of 416 
glioblastoma patients treated at a single institution between 1993 and 1999 reported resections of 
tumour volume in the order of 98% or greater to be associated with significant survival 
advantage (median survival 13 months, 95% CI 11·4–14·6 months versus 8·8 months (95% CI 
7·4–10·2 months; p < 0·0001).10  
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There is one randomized trial pertaining to surgical intervention, including elderly 
patients with glioblastoma. This small study of 30 patients assessed the role of debulking surgery 
compared to biopsy alone.11  Patients aged 65 or older with KPS >60 were randomized to open 
craniotomy and resection [14 patients with a median age of 70 (66-80)] or stereotactic biopsy [16 
patients with a median of age 72 (67 -79)]. Surgical resection resulted in superior overall survival 
(171 days (95% CI 146–278) vs. 85 days (95% CI 55–157) p = 0·0346). More recently, a case-
control study with a subgroup analysis of 52 patients aged 70 or over found a median survival of 
4·5 months and 3 months for surgical resection and needle biopsy respectively (p = 0·03).12 
Perhaps the most relevant trial for the topic is the Neuro-oncology Working Group of the 
German Cancer Society NOA-08 study which found extent of surgery to be an independent 
prognostic factor for overall survival among glioblastoma patients 65 years and older.13 
Furthermore, multivariate analysis of all patients (n=342) participating in the Nordic trial of 
standard vs. hypofractionated radiotherapy vs. chemotherapy alone in newly diagnosed 
glioblastoma patients 65 years of age or older also demonstrated a survival benefit favoring 
surgery over biopsy alone (biopsy versus resection HR 1·50 (1·17 -1·92) p =0·001).14 
 
Standard post-operative management for newly diagnosed glioblastoma 
The European Organisation for Research and Treatment of Cancer (EORTC) 26981-
22981/National Cancer Institute of Canada Clinical Trials Group (NCIC) CE.3 randomised phase 
III trial assessed the addition of temozolomide (TMZ) to radiotherapy (RT) in the concomitant 
and sequential adjuvant setting in glioblastoma patients aged 18-70.15  Median age was 56 (range 
19-71) and the selected population required Eastern Cooperative Oncology Group (ECOG) 
performance status of 0–2. The addition of TMZ resulted in a median survival benefit of 2·5 
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months; 14·6 months (95% CI 13·2- 16·8) compared with 12·1 months (95%CI 11·2 -13·0) for 
radiotherapy alone. The 5-year analysis of this trial confirmed a persisting advantage and this has 
become the standard of care post-surgical resection for patients less than 70 years of age and of 
appropriate performance status.16 In a recent review Laperriere et. al. noted that subgroup 
analysis of this trial demonstrated a trend to benefit in the more elderly subgroups, albeit with a 
less impressive hazard ratio and without reaching statistical significance. Specifically, there was 
diminishing benefit of combined treatment with increasing age (61-65 years: HR 0.64 p = 0.096 
and 66–70 years: HR = 0·78 p = 0·34) compared to the overall group (HR 0·6, 95%CI 0·5-0·7; 
p<0·0001).17 This may reflect less robust effects of the combined approach in the elderly or may 
be due to lower statistical power in the subgroup analysis. 
 
Radiation for elderly patients 
Randomized trials have long demonstrated a survival benefit from post-operative 
radiotherapy in the management of glioblastoma and more recently several trials have focused on 
the elderly. The French ANOCEF group found a median survival benefit of 12.2 weeks in favour 
of RT plus best supportive care (BSC) versus BSC alone.18 Patients aged 70 or older with a KPS 
>70 and a diagnosis of glioblastoma or anaplastic astrocytoma were randomized postoperatively 
to receive BSC [(42 patients (median age 73; range 70-85)] or BSC and 50 Gy in 1.8 Gy 
fractions to a clinical target volume (CTV) consisting of enhancing tumour with a 2cm margin 
[(39 patients (median age 75; range 70-84)]. Overall survival was 16·9 (95% CI, 13·4 to 21·4) 
and 29·1 weeks (95% CI, 25·4 to 34·9) respectively. No significant difference was detected with 
regards to quality of life; however, Health Related Quality of Life (HRQoL) assessments were 
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incomplete.  Cox proportional hazard modelling revealed that extent of surgery was associated 
with increased survival.  
Scott et al. performed a large retrospective review of elderly glioblastoma patients 
diagnosed between 1993 and 2005.19 The study sample of 2836 patients identified from the 
Surveillance, Epidemiology, and End Results (SEER) registry database had a median age of 76·9 
years (range 71·0–98·0). Kaplan-Meier analysis revealed median cancer-specific survivals of 8 
months for patients undergoing both surgery and postoperative radiotherapy, 4 months for 
radiation alone, 3 months for surgery alone and 2 months for neither surgery nor radiotherapy 
(log rank p<0·001). Multivariate analysis suggested radiotherapy significantly increased cancer-
specific survival after adjusting for tumour size, tumour location, surgery and patient 
demographics with a hazard ratio (HR) of 0·43 (95% CI, 0·38–0·49). 19 
The biological effect of radiation on tumour and normal tissues is dependent upon the 
provision of dose over time as well as intrinsic radio-sensitivity (α) and repair capability (ß). 
Glioblastoma has an alpha-beta ratio (α/ ß) = 8Gy (5·0–10·8)20 which is in the range of most 
tumours, while the alpha-beta ratio is approximately 2 for the normal central nervous system. As 
a result of this difference, hypofractionation reduces overall treatment time and may minimize 
the potential for tumor cell repopulation and provides a practical convenience for an elderly frail 
population. Roa et. al. randomized patients aged 60 or older to radiotherapy given as 60Gy in 30 
fractions (47 patients, mean age 72.4 yrs, SD 5·4) or a hypofractionated regimen of 40Gy in 15 
fractions (48 patients, mean 71·0 yrs, SD 5·5).21 While this study was not sufficiently powered to 
conclude equivalence of these two fractionation schedules it suggested no significant differences 
in OS [median 5.1 months for the standard RT arm versus 5·6 months for the shorter course (log 
rank p = 0·57)], survival at 6 months (44·7% standard RT versus 41·7% hypofractionated RT), 
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or HRQoL.  More patients required an increase of corticosteroid dose following the standard 
radiotherapy schedule compared to the hypofractionated course (p= 0·02). 
The Nordic trial incorporated a different hypofractionated radiotherapy schedule.14 There 
were 3 treatment arms including standard radiotherapy of 60Gy in 30 fractions, hypofractionated 
radiotherapy of 34Gy in 10 fractions or temozolomide 200mg/m2 days 1-5 every 28 days for up 
to 6 cycles. Standard radiotherapy (60Gy/30) was not routinely offered to elderly patients in 
some study sites so randomization between just the hypofractionated radiotherapy and 
temozolomide arms was permitted.  Two hundred and ninety one glioblastoma patients (initially 
aged 60 years or older then in view of EORTC 26981-22981/NCIC-CTG CE.3 the age eligibility 
was adjusted so that patients 60-65 years old fit for combined treatment were excluded) were 
randomized to standard radiotherapy (n=100), hypofractionated radiotherapy (n=98) or 
temozolomide alone (n=93). A further 51 patients were randomized to either hypofractionated 
radiotherapy (n=25) or TMZ (n=26) by those centers that did not offer 60Gy in 30 fractions as 
their standard care. 
The median age was 70 for both the hypofractionated and the standard radiotherapy 
groups. Median survival in the hypofractionated group was increased by 1·5 months compared to 
standard radiation in the three-arm comparison. Interestingly, on stratification by age, the 
advantage of hypofractionated radiation appeared better in patients over the age of 70 (7·0 (5·2–
8·8) versus 5·2 (4·0–6·3) months). Treatment completion according to protocol was more 
frequent with the hypofractionated schedule (95% versus 72%). Salvage treatment was received 
for a similar proportion of patients in both groups while reported toxicity was not different 
between groups.   
 
11 
 
Temozolomide and O-6-methylguanine-DNA methyltransferase  
The alkylating agent TMZ has activity in glioblastoma, and in combination with 
radiotherapy followed sequentially by a 6 month maintenance course represents the current 
standard of care for many patients. The mechanism of anti-tumour activity is believed to arise 
through methylation of DNA at the O-6 position of guanine by monomethyl-triazeno-imidazole-
carboxyamide (MTIC), a non-enzymatic chemical degradation product of temozolomide.22     
MGMT is a DNA repair protein implicated in resistance to alkylating agents.23  
Methylation of the MGMT promoter, located at 10q26, leads to suppression of MGMT gene 
expression and an increased likelihood of clinical benefit.23-25 Hegi et al. assessed the MGMT 
promoter methylation status of patients randomized in the EORTC trial 26981/ NCIC CE.3 
trial.25 Regardless of treatment arm, OS was longer in patients with MGMT promoter 
methylation; 18.2 months compared with 12.2 months [HR for death 0·45 (95% CI 0·32 - 0·61)]. 
The magnitude of this effect was more substantial for patients receiving TMZ compared with 
those receiving radiation alone (P=0·007 vs. P=0·06, log-rank test). Of note, the majority of 
patients allocated to radiotherapy alone received alkylating agent chemotherapy as salvage 
treatment further supporting the use of concomitant therapy ‘upfront’ in newly diagnosed 
patients.25 The prognostic significance of MGMT promoter methylation status was prospectively 
corroborated in the RTOG 0525 randomized study of TMZ dose density in the adjuvant setting. 
In this study, dose-dense TMZ (n=422) failed to demonstrate a survival advantage over standard 
dosing (n=411).26 The absence of a TMZ-free control arm did not allow distinction between 
prognostic and predictive properties. 
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For elderly patients not suitable for the combined modality approach, recent evidence 
supports consideration of TMZ alone particularly for tumors harbouring MGMT promoter 
methylation.27 Temozolomide alone was assessed in the Nordic study,14 which found longer 
survival for both TMZ alone and hypofractionated radiotherapy over standard radiotherapy in 
patients older than 65 years of age. Comparison of TMZ and hypofractionated radiotherapy 
revealed no significant difference in overall survival (7·4 versus 8·4 months HR 0·82 95%CI 
0·63-1·06). In the head to head comparison of TMZ versus hypofractionated radiation, 36% of 
the TMZ recipients had subsequent radiation and 29% of the hypofractionated group had salvage 
chemotherapy. MGMT promoter methylation status was available in 258 (75%) of 342 patients. 
Patients with MGMT promoter methylated tumors receiving TMZ survived 2.9 months longer 
than those with unmethylated tumors (HR 0·56, 95% CI 0·34-0·93, p=0·02). No survival 
advantage was identified based on MGMT promoter methylation status within the cohort 
receiving radiation (HR 0·97, 95% CI 0·69-1·38, p=0·81). Although the intent for the TMZ 
group was to complete six cycles, at least two cycles were administered to 86% of patients, and 
only 34% completed all six cycles. Haematological toxicity as well as nausea and vomiting were 
more frequent as would be expected in the TMZ cohort. In addition, a treatment-related death 
involving thrombocytopenia highlights that prescribing chemotherapy is not without the potential 
for serious toxicity. 
 
In the NOA-08 study,13 192 patients received TMZ (1 week on, 1 week off schedule 100 
mg/m2 days 1–7) and 178 patients received 60Gy radiotherapy alone over 6–7 weeks to the 
gross tumour volume (GTV) + 2 centimeters. Median overall survival was similar for the two 
treatment arms: 8·6 months in the TMZ group and 9·6 months in the radiotherapy group (HR 
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1·09, 95% CI 0·84–1·42, p non-inferiority=0·033). MGMT promoter methylation status was 
available in 55% of patients receiving TMZ and 57% of patients receiving radiation with a 
predictive benefit seen for patients receiving the alkylating agent in the context of MGMT 
promoter methylated tumors. Hematological toxicity, abnormal liver function tests, infections 
and thromboembolic events were more prevalent in the TMZ group.  
 
These trials found that MGMT promoter methylation is a predictive biomarker of benefit 
from TMZ, but not radiotherapy. The randomized international NCIC/EORTC/TROG study, 
which completed accrual in September 2013 (JP, personal communication), aims to address the 
potential benefit of combining short course radiotherapy (40Gy in 15 fractions) with concurrent 
and adjuvant TMZ in patients over 65 years who have had prior surgery/biopsy at diagnosis and 
are not deemed suitable for the standard radiotherapy regimen of 60Gy.28 MGMT status will be 
assessed in this study. 
A phase 2 ANOCEF study suggests that older age and poor KPS should not preclude the 
use of TMZ alone.29 This was a non-randomized study which recruited 70 patients with a median 
age of 77 (range 70-87) and a median KPS of 60 (range 30-60). Intriguingly this study found an 
improvement of KPS in excess of 10 for 23 (33%) of treated patients with 18 (26%) having a rise 
to 70 or more. A maximum of 12 cycles of TMZ was planned however the median number of 
cycles received was only 2 with 20% and 24% of patients having dose delays and dose 
reductions for hematological toxicity respectively. Grade 3 or 4 hematological toxicities were not 
insignificant with 13% experiencing grade 3-4 neutropenia and 14% grade 3-4 
thrombocytopenia. No deaths were attributed to treatment. Although only 44% of patients were 
able to have tumor material assessed for MGMT promoter methylation, this study again 
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demonstrated its predictive role with a hazard ratio for death of 2.307(95% CI 1.073 to 4.962) for 
patients with unmethylated MGMT promoter status (P=0·03). This phase II study introduces the 
question – should more elderly patients with poor performance status be primarily treated with 
TMZ monotherapy? Or should TMZ monotherapy be employed only in those whose tumor 
harbors a methylated MGMT promoter?    
Although MGMT promoter methylation status is increasingly available it still not used in 
all centres. In the future increasing evidence favoring MGMT testing is likely to demand more 
widespread availability; for example the European Association for Neuro-Oncology (EANO) 
guideline for the diagnosis and treatment of malignant gliomas has already declared that MGMT 
promoter methylation status testing is standard of care30.  There have been some controversies 
regarding the methodology of MGMT testing, with some centers preferring pyrosequencing and 
others utilizing PCR. Immunohistochemistical assessment of MGMT does not appear to correlate 
with overall survival.31 
 
Bevacizumab 
Three uncontrolled studies indicate that the vascular endothelial growth factor (VEGF) 
antibody bevacizumab may have increased activity in elderly patients with glioblastoma.32-34 In 
2014, the efficacy of bevacizumab in newly diagnosed glioblastoma patients has been reported 
by two large, placebo-controlled, randomized trials.35,36 The Avastin in Glioblastoma (AVAglio) 
phase III study evaluated the effect of the addition of bevacizumab to focal radiotherapy with 
concurrent TMZ, to the adjuvant component and then beyond the adjuvant component until 
progression.34 Although improved progression-free survival (HR 0·65 (0·56–0·75)), preservation 
of baseline quality of life and performance status were reported, there was no improvement in 
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overall survival. Stratified by age over 70 years, the statistical significance with regards to PFS 
was lost [HR 0·78 (0·46–1·33)]; however this may reflect an issue of statistical power and small 
subgroups rather than a lack of clinical efficacy.  The RTOG 0825 trial, sharing a similar design, 
also failed to demonstrate an overall survival benefit35 but in contrast to the AVAglio study, a 
greater deterioration clinically assessed by patient reported outcome questionnaire, was evident 
in the bevacizumab group. There were differences in the design of these two studies that may 
influence determination of progression and patient reports outcomes.  Radiological assessment in 
the RTOG 0825 study was by serial measurement of cross-sectional diameter and use of the 
international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)37 
committee whereas the AVAglio study utilized an adaptation of the Macdonald criteria, similar 
to the newer RANO criteria, which takes into account the issues of pseudoprogression, 
pseudoresponse and changes in the non-enhancing disease.38  Ongoing discussion and analyses 
may further clarify the apparent discordant results with regard to progression-free survival  in 
these two pivotal trials.  
 No clinical or tissue based biomarkers have yet been prospectively shown to be 
associated with benefit from bevacizumab although patients with glioblastomas harbouring a 
proneural subtype may derive the most benefit.39 At present bevacizumab has no role in the 
standard upfront treatment of glioblastoma; however, future clinical trials may attempt to target 
specific groups of patients defined by sets of biomarkers. The randomized Avastin plus 
Radiotherapy in Elderly Patients with Glioblastoma (ARTE) study, a phase II trial, will explore 
whether the addition of bevacizumab to radiotherapy improves outcome in elderly patients with 
newly diagnosed glioblastoma without MGMT promoter methylation (M. Weller, personal 
communication). 
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Symptomatic management  
Glioblastoma can cause many difficult symptoms ranging from fatigue to those 
associated with raised intracranial pressure. Seizures may often occur as well as cognitive, motor 
or sensory deficits occurring in a location-dependent manner. Corticosteroids are often required 
to control symptoms of cerebral edema and their utility over time must be balanced with 
potential side effects such as proximal myopathy, steroid-induced diabetes, and osteoporotic 
fractures which can be debilitating. Furthermore, corticosteroids may reduce the benefit from 
TMZ in the most promising MGMT promoter methylated subgroup.40 Anti-seizure medications 
are also often warranted.  There is no randomised evidence pertaining to palliative care in the 
glioblastoma setting. However, based on a randomised study in non-small lung cancer, which 
demonstrated the addition of palliative care not only improved quality of life but also increased 
overall survival, many would advocate the early incorporation of palliative care support.41  
 
Population-based retrospective studies 
For glioblastoma, like many other cancers, results from randomized clinical trials (RCTs) 
may not reflect ‘real world” outcomes as described in population based studies. Several large 
population based studies have shown that many elderly patients do not receive the ‘gold 
standard’ treatment.  For example, despite the increasing body of evidence regarding the 
important benefit of resection rather than biopsy, numerous international pattern of care 
studies42-46 demonstrate a much higher rate of biopsy alone rather than attempted resection in the 
elderly population. 
The SEER database study published by Scott et. al. reported that among 2836 patients, 
only 46% of those over the age of 70 received both surgery and radiotherapy, with omission of 
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treatment associated with poorer survival.19 A similar SEER study of 4,137 patients with 
glioblastoma, aged 65 or older, reported a median overall survival of 4 months and described age 
to be associated with lower odds of resection and provision of RT or chemotherapy.19 The 
Princess Margaret Cancer Centre published outcomes of 131 patients aged greater than 70 
treated in the ‘temozolomide era’ between 2004 and 2008.47  Elderly patients were more likely to 
receive best supportive care or ‘palliative’ doses of radiotherapy with only 1 patient receiving 
60Gy in 30 fractions in combination with TMZ. Only 6 patients (5%) received TMZ post-
radiation, with only a median of 2.5 cycles administered.  A retrospective review of 235 patients 
aged 65 or over treated between 2006 and 2013 at the Odette Cancer Center in Toronto provides 
a more contemporary overview regarding provision of care in the elderly setting.48 With a 
median survival of approximately 2 months, 19% of patients were deemed not suitable for active 
treatment. 
There is a likely another subgroup of elderly patients not reflected in statistics who might 
be presumptively diagnosed on radiological investigations (e.g. imaging for suspected stroke) but 
for various reasons (e.g. comorbidities, patient and family preference) do not proceed even to a 
biopsy. Of course, in certain scenarios, e.g. bedbound patient with dementia, it may be 
inappropriate to pursue active management. 
Survivorship in the ‘real world’ would appear less favorable to that quoted in RCTs and 
may be a reflection of both physician preference to not to administer treatment in a group 
previously not studied as well as patient choice. The definition of ‘elderly’ varies across clinical 
trials and may appear to limit the ability to cross-compare data from these studies. That said, the 
NOA-08 trial had a median age of 72 (66-84) years in the TMZ arm and 72 (66-82) years in the 
RT arm. Age as a continuous variable or dichotomized at age 70 was not an independent 
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prognostic factor for either OS or event-free survival13; thus the association with age may not be 
as important in patients older than 70 years. Patients from population-based studies are clearly 
different that those included in the randomized trials. A patient-centered approach is important, 
as in all aspects of medicine, and treatment decisions need to involve a patient’s own preferences 
and goals of care should be a focus early in the discussion regarding management.   
 
Practical aspects: 
Practical considerations such as performance status and even the ability of the patient to 
get to appointments can also come into play, as many of these patients are no longer driving. For 
example, a mobile elderly patient with a poor short-term memory, but with a strong family 
network advocating for active treatment, is far more likely to be treated than a socially isolated 
patient. If a cognitively intact patient with poor mobility is keen for treatment; again the presence 
of supportive family will often make a difference impacting on decision-making. 
Often rehabilitation is not offered for glioblastoma patients postoperatively. However, 
there is evidence that postoperative rehabilitation in this setting is just as useful as in the stroke 
setting49,50 and should be considered where possible. There are observational studies which show 
improvement in patients’ functional status during the course of rehabilitation therapy, including 
the functional independence measure (FIM)51,52 and referral for rehabilitation is advocated.53 
Elderly patients and their caregivers may have numerous symptoms or challenges ahead. 
Challenges include treatment and tumor-related symptoms and deficits, seizures, headaches, 
communication difficulties (e.g. expressive or receptive aphasia), personality and behaviour 
changes (e.g. frontal syndrome with disinhibition and emotional lability), poor concentration, 
poor memory, fatigue, weakness, mobility; hemiparesis, impaired judgement/insight and 
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depression (reactive versus major). These challenges can be even more difficult to manage in the 
setting of comorbidities and polypharmacy often faced by elderly patients. 
The clinical journey is a complex one and can involve interaction with many health 
professionals- including neurosurgeon, radiation oncologist (and radiation therapists), medical 
oncologist, palliative care physician, occupational therapist, physiotherapist, neurologist, 
endocrinologist (for steroid-induced diabetes) or diabetic educator, social worker, pharmacist, 
psychologist, speech pathologist etc. and ideally a cancer care coordinator should be available, 
where possible, to help the patient navigate through this difficult pathway. 
Caregiver burnout is also very important for clinicians to be aware of. Recent studies 
have demonstrated that the global quality of life is often poorer in the caregiver than in the 
patients themselves.54,55 Often, in the elderly setting, a spouse (if there is one) has their own co-
morbidities to deal with and struggles to manage both physically and emotionally with the 
complexities involved with caring for a partner with glioblastoma.  
 
Conclusion and recommendations 
Selecting the appropriate treatment for an elderly patient with a newly diagnosed 
glioblastoma is challenging and a patient-centred approach is essential. Randomised evidence to 
guide treatment decisions is emerging (table 2) and there is less reason for nihilism. Initial 
consideration should include the appropriateness and extent of surgical intervention. With frailty 
and potential comorbidities there may be increased perioperative complications and prolonged 
recovery; however, maximal safe surgical resection should be considered. Subsequent 
management should incorporate initial symptomatic management including titration of 
corticosteroids and suitable anti-seizure medication if required.  Early introduction of palliative 
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care may have a role in many patients. Management should be based upon the fitness of the 
patient, performance status, and MGMT promoter methylation status (Figure 2).56 Standard 
radiotherapy of 60Gy in 30 fractions with concurrent and adjuvant TMZ can be utilized for most 
patients under the age of 70 and of appropriate fitness. In patients over the age of 70 there is 
evidence of efficacy for both radiotherapy alone and TMZ monotherapy respectively; the results 
of the NCIC-CTG/EORTC/TROG clinical trial will assess the benefit of hypofractionated 
radiotherapy with concurrent TMZ compared to radiotherapy alone. Most patients over 70 years 
of age appear not to benefit from conventional radiation schedules such as 60Gy in 30 fractions 
and a hypofractionated schedule is recommended. We acknowledge that some practitioners 
continue to recommend radical treatment (60Gy in 30 fractions with TMZ) for fit patients over 
the age of 70; however there are no randomized data to support this practice. MGMT may turn 
out to be even more important in the setting of elderly patients than in younger patients in terms 
of guiding management decisions. Ideally MGMT promoter methylation status should be 
determined on all patients 65 years and older. Patients lacking MGMT promoter methylation 
should be considered for a course of hypofractionated radiation therapy alone while those with 
methylated tumors may be offered temozolomide alone. Selection of these treatments requires an 
interdisciplinary discussion of the risks and benefits of RT versus TMZ, incorporation of the 
patient’s own goals of care, and patient preference.  
Some of the current algorithms for elderly glioblastoma patients are based on 
extrapolations from small and underpowered studies, but hopefully over the next few years, 
higher levels of evidence from larger maturing phase III studies will ensure future 
recommendations are more robust. 
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Table 1:  Average age adjusted incidence per 100,000 and relative survival for GB stratified by 
age (CBTRUS)(2) 
 
Age (years) Average age adjusted 
incidence per 100,000 
1yr Relative 
Survival 
2yr Relative 
survival 
5yr Relative 
survival 
45-54 3.62 52.7% 20.8% 5.9% 
55-64 8.08 40.7% 14.2% 3.8% 
65-74 13.09 23.7% 7.2% 1.7% 
75-84 14.93 9.2% (≥75) 2.6% (≥75) 0.8% (≥75) 
≥85  9.24 
Table 1
Click here to download Table: MasonTable 1.docx 
Table 2: Randomised clinical evidence for elderly GB patients. 
Title Treatment Arm Number 
of 
patients 
Age  
Median (Range) 
Outcome 
Debulking or biopsy of 
malignant glioma in elderly 
people – a randomized study
11
  
Stereotactic biopsy 
Open Craniotomy/ Resection 
16 
14 
72 (67-79) 
70 (66 – 80) 
85 days (95% CI 55–157)   
171 days (95% CI 146–278) 
(p = 0.035) 
Radiotherapy for Glioblastoma 
in the Elderly
18
 
Best Supportive Care (BSC) 
Radiotherapy 50Gy in 28 
fractions with BSC 
42 
39 
73 (70 -85) 
75 (70-84) 
16.9 weeks (95% CI, 13.4 to 21.4) 
29.1 weeks (95% CI, 25.4 to 34.9) 
HR for death in RT Group 0.47 (95%CI 0.29 to 
0.76; p = 0.002 by the log-rank test) 
Abbreviated Course of 
Radiation Therapy in Older 
Patients With Glioblastoma 
Multiforme: A Prospective 
Randomized Clinical Trial 
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Standard radiotherapy (60·0 Gy in 
2·0 Gy fractions over 6 weeks) 
Short-course regimen (40 Gy in 
15 fractions over 3 weeks) 
47 
 
48 
Mean 72.4 (SD 5.4) 
 
Mean 71 (SD 5.5) 
 
 
Median survival 5.1 months 
 
Median survival 5.6 months 
 
(HR 0.89; 95% CI, 0.59 to 1.36; p = .57) 
Temozolomide chemotherapy 
alone versus radiotherapy alone 
for malignant astrocytoma in 
Temozolomide alone 100 mg/m 
2
 
given on days 1–7 of 1 week 
every 14 days 
195 
 
 
72 (66–84) 
 
 
8.6 months(95% CI 7.3–10.2)  
 
 
Table 2
Click here to download Table: MasonTable 2.docx 
the elderly: the NOA-08 
randomised, phase 3 trial
13
  
Radiotherapy 60·0 Gy, 
administered over 6–7 weeks in 
30 fractions of 1·8–2·0 Gy 
178 71 (66–82) 9.6 months (8.2–10.8) 
 
(HR 1·09, 95% CI 0·84–1·42, p non inferiority=0·033) 
Temozolomide versus standard 
6-week radiotherapy versus 
hypofractionated radiotherapy 
in patients older than 60 years 
with glioblastoma: the Nordic 
randomised, phase 3 trial
14
 
Standard radiotherapy (60·0 Gy in 
2·0 Gy fractions over 6 weeks) 
 
Hypofractionated radiotherapy 
(34·0 Gy in 3·4 Gy fractions over 
2 weeks 
 
Temozolomide (200 mg/m
2
 on 
days 1-5 of every 28 days for up 
to six cycles) 
100 
 
 
98 
 
 
 
93 
70 years (60–80) 
 
 
70  (60–83) 
 
 
 
70 (60–88) 
 
 
6·0 months (95% CI 5·1-6·8) 
 
 
7·5 months (95% CI 6·5-8·6) 
 
 
 
8·3 months (95% CI 7·1-9·5) 
 
Figure 1: Overall Survival of Glioblastoma Patients Treated in Ontario, Canada 
Stratified by Decade of Age 
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Figure 2: Flow diagram of treatment considerations for elderly Glioblastoma patients 
(a) 65-70 and (b) >70 
 
*Outcome awaited of NCIC CTG CE6  
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